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 Clostridioides difficile (Clostridium difficile) is a spore-forming bacterial pathogen 
responsible for hundreds of thousands of infections each year in the United States. C. difficile 
outbreaks are common in hospitals because C. difficile spores can persist for months on surfaces 
and are resistant to many disinfectants. Despite the significant disease burden that C. difficile 
represents, we know surprisingly little about the factors necessary for C. difficile to colonize and 
persist in the mammalian intestine. Previous work demonstrated that the signaling molecule 
cyclic diguanylate (c-di-GMP) regulates a variety of processes in C. difficile including 
production of the toxins that are required for disease symptoms. Using monolayers of human 
intestinal epithelial cells, we demonstrate that c-di-GMP promotes attachment of C. difficile to 
intestinal epithelial cells. We also demonstrate that regulation of type IV pili (TFP) by c-di-GMP 
promotes prolonged adherence of C. difficile to epithelial cells in vitro. C. difficile mutants 
lacking TFP were cleared more quickly than the parental strain during single strain mouse 
infections and were outcompeted by the parental strain during in vivo competition experiments in 
mice. Thus, our data provides evidence that TFP promote persistence of C. difficile in the 
intestine. To determine what other genes c-di-GMP regulates in C. difficile, we performed RNA-
sequencing comparing the transcriptome of C. difficile with elevated c-di-GMP to that of C. 
difficile with basal levels of c-di-GMP. We demonstrate that c-di-GMP regulates the expression 
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of 166 genes greatly expanding the known members of the c-di-GMP regulon. We demonstrate 
that c-di-GMP regulation of several transcripts in C. difficile is dependent on c-di-GMP sensing 
riboswitches present in the 5’ untranslated regions of these transcripts. Our results also show that 
c-di-GMP regulates a number of cell envelope proteins in addition to TFP and flagella. These 
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CHAPTER 1: INTRODUCTION 
 Clostridioides difficile (formerly Clostridium difficile) (1) is a Gram-positive bacterial 
pathogen that is responsible for approximately half a million infections yearly in the United 
States and an estimated 4 billion dollars in associated healthcare costs (2). C. difficile infections 
(CDI) are one of the most common hospital-acquired infections. CDI can range in severity from 
mild diarrhea to potentially life-threatening pseudomembranous colitis and toxic megacolon (3, 
4). Disease symptoms are mediated in part due to the secretion of toxin(s), TcdB and/or TcdA, 
and strains lacking these toxins do not cause disease (5-8). Despite the current prevalence of 
these infections in the healthcare system, the importance of C. difficile as a pathogen has only 
been appreciated for a few decades.  
 
DISCOVERY OF CLOSTRIDIOIDES DIFFICILE 
 C. difficile was first isolated in 1935 from the stools of healthy infants (9). The 
researchers named it Bacillus difficilis owing to its rod-like shape and the difficulties they 
experienced when trying to culture the bacterium (9). Despite its prevalence in the stools of 
healthy infants, they discovered that C. difficile was highly virulent in guinea pigs and rabbits, 
killing nearly all the animals into which bacterial cultures were injected. Similar effects were 
observed when they injected bacteria-free media from the C. difficile cultures into guinea pigs; 
however, boiling the media rendered it non-toxic. This finding indicated that the bacteria were 
secreting a heat-labile toxin and that this toxin was responsible for causing disease (9). However, 
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because the bacterium was isolated from healthy infants with no signs of acute bacterial 
infection, it was unclear whether C. difficile was virulent in humans. In the early 1960s, on the 
basis of eight C. difficile samples isolated from patients, Smith and King concluded that there 
was no solid evidence that C. difficile was “anything other than a secondary invader” and that the 
bacterium was unlikely to cause significant disease in humans (10). They determined that reports 
of disease attributed to C. difficile were likely coinfections with other more virulent bacteria (10). 
 By this point, surgeons had noted high rates of pseudomembranous colitis, a severe 
inflammation of the colon, among patients undergoing invasive surgery, but the cause was 
assumed to be Staphylococcus aureus infection (11, 12), and patients were successfully treated 
with the antibiotic vancomycin (13). In cases where S. aureus was unable to be cultured from 
patient stools, the source of the pseudomembranous colitis remained mysterious. In 1974, 
researchers reported high rates of diarrhea (21%) and pseudomembranous colitis (10%) in 
patients receiving the antibiotic clindamycin (14). Additional reports from other hospitals 
mirrored the findings associating clindamycin with diarrhea and pseudomembranous colitis, thus 
renewing interest in determining the cause of antibiotic-induced colitis (15, 16).  
 For a number of years, scientists had observed that treatment of hamsters with certain 
antibiotics caused the hamsters to develop colitis that was similar to the pseudomembranous 
colitis seen in patients (17). A group of scientists at Tufts University tested samples from 
hospital patients with pseudomembranous colitis and determined that they contained a cytotoxin 
that was neutralized by antibodies to Clostridium sordellii toxin (18, 19). Following up on these 
findings, a separate set of researchers attempted to isolate the bacterium producing this cytotoxin 
from the feces of hamsters with clindamycin-associated enterocolitis (20, 21). They successfully 
isolated C. difficile from these hamsters and demonstrated that the bacteria produced toxins that 
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were neutralized by C. sordellii antitoxin (21). These results were quickly corroborated by other 
groups using the hamster model of antibiotic-induced enterocolitis (22). These experiments 
finally demonstrated that C. difficile was a bona fide pathogen and put an end to the era where 
CDI was spuriously classified as S. aureus enterocolitis.  
 
THE C. DIFFICILE LIFECYCLE AND TRANSMISSION 
 C. difficile is an obligate anaerobic bacterium, so its growth is restricted to environments 
where oxygen is extremely limited (23). C. difficile and a variety of other Clostridia are common 
members of the gut microbiota in many mammalian species, including humans. Many Clostridia 
are commensal within the gut and may even provide a variety of benefits to their host (24-26). 
While the mammalian colon is largely anaerobic, the extracorporeal atmosphere is replete with 
oxygen, so the bacteria need a way to survive outside the host in order to successfully be 
transmitted to new hospitable environments (27). C. difficile, as well as a variety of other Gram 
positive bacteria, survive exposure to oxygen and harsh environments by forming endospores 
(23). When triggered by environmental cues, these bacteria undergo sporulation, which results in 
the production of metabolically dormant spores that are resistant to a wide variety of 
environmental stresses (28-30). Many environmental cues that lead to sporulation are known in 
the model organism Bacillus subtilis (31). However, the histidine kinases that control sporulation 
initiation in B. subtilis are not conserved in the genome of C. difficile, and the signals regulating 
sporulation in C. difficile are largely unknown (30). C. difficile spores are not only resistant to 
oxygen, but they are also resistant to high temperatures, low pH, antibiotics, and many 
commonly used disinfectants (32-34). These spores can remain for weeks to months on 
contaminated surfaces (35, 36). The combination of their resistance to disinfectants and their 
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potential to contaminate areas for long periods of time makes these spores particularly 
problematic in healthcare settings (37).  
 Once the spores are ingested by a susceptible host, the spores are well adapted to survive 
gastric passage and reach the intestines, where a combination of bile acids, calcium, and amino 
acids is sensed by the spores and triggers their germination into actively growing “vegetative” C. 
difficile (38, 39). If there is a favorable environment for the growth of C. difficile, the bacteria 
may colonize and grow within the lower GI tract. The factors necessary for C. difficile to 
colonize the colon remain unclear. Toxigenic C. difficile strains secrete glucosylating cytotoxins 
that are critical for disease symptom development (discussed below). In response to poorly- 
defined environmental cues, a subset of the C. difficile population within the intestine undergoes 
sporulation (40, 41). These spores are expelled in feces with the potential to spread to new 
animal or human hosts (40, 41). In hospitals and elderly care facilities, the rooms of C difficile 
patients are sometimes quarantined and disinfected with hydrogen peroxide to prevent the spread 
of C. difficile spores to other susceptible patients (34, 42, 43).  
 Despite its association with disease, C. difficile is a relatively frequent constituent of the 
human gut microbiota, with approximately 2-5% of the adult population asymptomatically 
colonized with the bacterium at any given point (44). While a portion of these C. difficile strains 
do not encode toxins and are thus nonpathogenic, many seem capable of producing toxins but are 
nonetheless carried asymptomatically (44, 45). C. difficile can also be found as a component of 
the microbiota in other animals, including pigs, dogs, and birds (45-47). Many of these strains 
are non-toxigenic, however, toxigenic strains with the potential to cause disease are also isolated 
from these potential animal reservoirs (45-47). The extent to which these animal reservoirs 
contribute to C. difficile spread to humans is unknown, but there is evidence that transmission 
5 
from pigs may have played an important role in the emergence of new strains of C. difficile in 
the Netherlands (46, 48).  
RISK FACTORS FOR CDI 
 Healthy individuals with undisturbed intestinal microbiota are normally resistant to C. 
difficile associated disease, but disruptions of the intestinal microbiota and impairment of the 
immune system are risk factors for developing CDI (3, 49, 50). Additionally, the elderly have 
much higher rates of CDI and a worse prognosis upon diagnosis (51). Recent studies have 
revealed that resistance to CDI is multifactorial and can be affected by the presence of other 
bacteria in the intestine that promote or inhibit the growth of C. difficile (52, 53).  
 The interactions between C. difficile and other members of the gut microbiota are 
complex, but a few key relationships have been demonstrated over the last few years. 
Bacterioides thetaiotaomicron, a common member of the gut microbiota and a common 
ingredient in probiotic supplements, encodes a sialidase enzyme that cleaves sialic acid from 
mucins in the mucus of the colon (54). C. difficile is able to import the cleaved sialic acid and 
use it as an energy source (54). Animal experiments demonstrated that the number of C. difficile 
in the colon was enhanced when mice were colonized with both C. difficile and B. 
thetaiotaomicron compared to C. difficile alone. These data suggest that B. thetaiotaomicron is a 
poor choice for probiotics in C. difficile patients as these bacteria can promote growth of the 
pathogen in the mammalian colon (54, 55).  
 An intestinal microbiome rich in bacteria of the class Clostridia is often associated with 
resistance to C. difficile colonization in hosts (53, 56, 57). Clostridium scindens, a distant relative 
of C. difficile, is one bacterium that provides resistance to CDI (56). C. scindens produces an 
enzyme that converts primary bile acids in the gut to secondary bile acids. Binding of bile acids 
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such as cholate and taurocholate to receptors on C. difficile spores promotes the germination of 
spores into actively growing bacteria (39, 58). C. scindens converts the primary bile acid cholate 
into deoxycholate, a secondary bile acid that inhibits the growth of vegetative C. difficile. 
Members of the bacterial families Lachnospiraceae and Ruminococcaceae are also associated 
with enhanced resistance to C. difficile colonization, but the exact mechanism of this protection 
has not been determined (57). Some of the species in these families can also convert cholate to 
deoxycholate, so their presence in the microbiota may inhibit C. difficile growth due to increased 
deoxycholate concentrations in the gut (59).  
 Treatment with broad spectrum antibiotics such as clindamycin shifts the composition of 
the gut microbiota by removing many commensal bacteria (53, 60, 61). Levels of 
Ruminococcacea and Lachnospiraceae (including C. scindens) are decreased following antibiotic 
treatment (53, 62). Accordingly, the intestines of mice treated with clindamycin have much 
lower levels of C. difficile-inhibiting bile acids like deoxycholate and higher levels of 
germination-promoting taurocholate compared to untreated mice, which are resistant to C. 
difficile colonization (52, 60). The cecal contents of animals with high levels of deoxycholate 
have been shown to inhibit C. difficile growth and have led to the prospect of treating patients by 
increasing the content of deoxycholate in the colon (52). However, high concentrations of 
deoxycholate in the gut have been identified as a risk factor for colon cancer indicating that there 
may be unintended side effects to increasing deoxycholate levels (63, 64).  
 Age is another factor that can affect the severity of CDI (65, 66). Infants often have very 
high rates of C. difficile recovery in the stools with colonization rates as high as 70% compared 
to ~3% in adults (67, 68). Although many of the C. difficile strains recovered from infants are 
toxigenic, these infants are usually asymptomatic carriers of the bacterium (44, 67). The reason 
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for the lack of disease in infants is unclear (44). One current hypothesis is that a combination of 
toxin antibodies in breast milk and a lower incidence of toxin binding receptors in infants render 
them relatively insensitive to the effects of the C. difficile toxins TcdA and TcdB (44, 69). 
Infants are not immune to disease, however, and there has been an increase in the number of 
infants with symptomatic CDI in the past decade, possibly due to an increase in the prevalence of 
“hypervirulent” C. difficile strains such as those of ribotype 027 (44). In contrast to infants, the 
rates and severity of CDI are much higher among the elderly, with most deaths from CDI 
occurring in patients over age 65 (65, 66, 70). Some of this increase may be due to the increased 
likelihood of comorbidities in elderly patients, but other factors are likely at play (70, 71). For 
example, immune system dysfunction is also associated with higher rates of C. difficile infection, 
and immune dysfunction is much more common in elderly patients (72). Recently, it was shown 
that high calcium levels in the gut promote the germination of C. difficile spores (73). Calcium 
absorption is reduced with age, so it is possible that calcium levels in the intestines of elderly 
patients enhance their risk of CDI, but this has not been demonstrated experimentally (74, 75). 
There are also age-related shifts in the composition of the gut microbiota, with elderly patients 
showing decreases in the diversity of obligate anaerobic bacteria and increases in clostridial 
species (49). These shifts in the microbiota may also contribute to the increased susceptibility to 
CDI among the elderly.  
 
PATHOGENESIS OF CDI 
 C. difficile pathogenicity is in large part driven by the actions of cytotoxins produced by 
the vegetative bacteria in the colon (71). All strains known to cause disease produce one or two 
large glucosylating toxins, TcdA and TcdB (7, 71). These proteins are made up of four domains: 
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an N-terminal glucosyltransferae domain, an autoprotease domain, a delivery domain, and a 
CROP domain that is involved in receptor binding (76). The two toxins are 48% identical in their 
amino acid sequence, and they differ primarily in regions involved in receptor binding (76, 77). 
These toxins bind to receptors on the surface of target cells and are internalized via receptor-
mediated endocytosis. Once inside the cell, the toxins are cleaved by the autoprotease domain, 
releasing the glucosyltransferase domain into the cytoplasm (76, 78). The glucosyltransferase 
domain uses UDP-glucose as a substrate to glucosylate Rho family GTPases in the host cell (76, 
77). The glucosylation of Rho proteins renders them unable to bind to their targets and has a 
variety of consequences for the host cell (79-81). Because Rho family GTPases are critical for 
actin cytoskeleton regulation and the maintenance of tight junctions between cells, glucosylation 
of Rho proteins leads to disruption of the tight junctions between target cells (76, 82). 
Additionally, the glucosylation of these Rho proteins triggers controlled cell death pathways in a 
cell-type and toxin-type dependent manner (76). Activation of the inflammasome by 
glucosylated Rho proteins triggers production of IL-1β and drives inflammation in a mouse 
model of CDI (83, 84). The combination of cell death, tight junction breakdown, and 
inflammasome activation leads to extensive inflammation in the colonic epithelium, disruption of 
the epithelial barrier, and the diarrhea associated with CDI (71, 81-84).  
 
REGULATION OF TOXIN PRODUCTION 
 The genes encoding the C. difficile toxins are located on a genetic region known as the 
pathogenicity locus (PaLoc) (85). The PaLoc also contains genes encoding an alternative sigma 
factor (TcdR), a putative anti-sigma factor (TcdC), and a holin protein involved in toxin 
secretion (TcdE) (85-88). Transcription of the toxin genes is positively regulated by TcdR, a 
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sigma factor that directs RNA polymerase to the promoters of tcdA and tcdB allowing 
transcription of the genes (88). TcdC has been reported to be a negative regulator of toxin 
production in some studies, but mutation of tcdC did not alter toxin production in another study, 
leaving the role of TcdC in toxin regulation unclear (87, 89, 90).  
A number of proteins are known to regulate the transcription of the toxin genes. These 
include the transcription factors CcpA, CodY, Spo0A, SigH, and SigD (40, 91-96). Toxin 
synthesis has long been known to be repressed by an abundance of nutrients, in particular 
glucose (97, 98). CcpA is a global transcriptional repressor that represses transcription of genes 
related to the transport and catabolism of other carbon sources when glucose (a preferred carbon 
source) is present (99, 100). In most bacteria, when glucose levels are high inside the cell, the 
HPr kinase phosphorylates CcpA and activates it, however HPr is not sufficient for CcpA 
activation in C. difficile (91, 99). Activated CcpA then binds to sequences known as cre sites and 
inhibits transcription of downstream genes (99). In C. difficile, CcpA binds to cre sites 5’of tcdR, 
inhibiting tcdR transcription and ultimately repressing expression of tcdA and tcdB (91, 100). 
CodY also controls expression of tcdR in response to nutrient availability (101). When activated 
by high intracellular concentrations of branched chain amino acids and GTP, CodY binds with 
high affinity to regions 5’ of the target genes (including tcdR) and represses their expression 
(102). When nutrient levels become limiting, CodY repression is removed and expression of the 
toxin genes resumes (101). Transcriptome analyses of other major transcriptional regulators in C. 
difficile, namely SigH and Spo0A, suggest additional pathways control the expression of the 
toxin genes. Mutation of sigH results in increased toxin levels (40, 93). However, the effect of 
SigH on toxin production is likely indirect because no SigH promoter is present upstream of 
tcdA, tcdB, or tcdR (93, 103, 104). There are conflicting reports on the effect of spo0A mutation 
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on toxin production (103, 105). One group demonstrated that a spo0A mutant produced less 
TcdA than the parental strain, and they also showed that the supernatant of the spo0A mutant was 
less cytopathic to Vero cells (105). However, another group showed that Spo0A was bound to 
the promoter upstream of tcdB, but they did not observe any difference in the cytopathic effect of 
this strain relative to the parental strain (103).  
 The last of the demonstrated transcriptional regulators of toxin production is the flagellar 
sigma factor, SigD (95, 96). The link between toxin production and flagellar biosynthesis in C. 
difficile was first demonstrated when mutations in flagellar genes led to large changes in 
transcription of the genes within the PaLoc (106). Our group demonstrated that the link between 
flagella and toxin production is the sigma factor, SigD (95). SigD is responsible for the 
transcription of the genes involved in later stages of flagellum assembly (96, 107). SigD also 
regulates a number of genes in C. difficile that are unrelated to flagellar function (96). Work from 
our lab and others showed that SigD regulates the transcription of the toxin genes by directly 
promoting transcription of the toxin transcriptional regulator, TcdR (95, 96).  
 
COLONIZATION FACTORS OF C. DIFFICILE 
 Much of the research on C. difficile has focused on the toxins because they are sufficient 
for disease in animal models, and their functions can be studied in detail without the need for 
manipulation of C. difficile. However, the factors that C. difficile uses to colonize and persist 
within the gut are largely unknown, despite the fact that colonization of the intestinal mucosa is a 
requisite step in disease development (108). Several C. difficile proteins have been implicated in 
binding to host cells in vitro. These include SlpA, FbpA, and Cwp66. SlpA, the major 
component of the C. difficile S-layer, binds to host cells, and antibodies raised against SlpA 
11 
decrease C. difficile binding to Hep2 and Caco-2 cells, suggesting a role for SlpA in promoting 
host cell attachment (109, 110). In the C. difficile strain 630Δerm, a mutation in fbpA, which 
encodes a putative fibronectin binding protein, resulted in increased adherence to HT-29 cells but 
displayed a modest decrease in cecum colonization relative to the parent strain in monoxenic 
mouse infections (111). Finally, antibodies raised against a C. difficile cell wall protein, Cwp66, 
reduced binding to Vero cells in vitro, suggesting that Cwp66 is involved in host cell attachment 
(112). With the exception of the slight defect in cecum colonization in the fbpA mutant, none of 
these putative colonization factors have been shown to affect colonization in animal models of 
CDI (111). 
 While not required for initial colonization of the intestine, the sporulation master 
regulator Spo0A was shown to be important for persistence in mouse infections (40). In mouse 
co-infections, the spo0A mutant bacteria were recovered in equal numbers to the parental strain 
at early time points, but were outcompeted by the WT bacteria at later times during infection 
(40). Spo0A is a transcription factor that controls the expression of a large number of genes in C. 
difficile, so it is unclear whether this persistence defect is due to effects on sporulation or other 
pleiotropic effects from the loss of spo0A (113). 
  Perhaps the most well-studied colonization factor in C. difficile is the flagellum. Flagella 
are used for motility, but they can also function as adhesins to promote binding to a surface in a 
number of bacteria (114). C. difficile produces peritrichous flagella that are used for motility, and 
flagellum production is also necessary for optimal colonization of animal models in certain C. 
difficile strains (106, 115, 116). In strain 630Δerm (an erythromycin-sensitive derivative of the 
historical CD630 strain), mutation of fliC and fliD resulted in increased adherence to Caco-2 
intestinal epithelial strains in vitro and increased virulence in hamsters (116). In strain R20291, a 
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more recently isolated epidemic isolate of C. difficile, bacteria lacking flagella were attenuated 
for colonization in single-strain infections of mice (116). A mutant with paralyzed flagella was 
able to colonize to nearly the same levels as the parental strain indicating that the flagellum itself 
is more important than flagellar motility for colonization in the R20291 strain (116). Differences 
in the role of flagella in colonization in these two strains may be due to differences both in the 
flagellin protein and in flagellar glycosylation (117). Alternatively, the differences in these 
experiments could be explained by the differing ability of these two strains to phase vary 
production of the flagellum (118). Flagella are additionally important in C. difficile pathogenesis 
due to the co-regulation of toxin gene expression with flagellar gene expression via the sigma 
factor, SigD (95, 96). Thus, factors that regulate flagella are also likely to regulate toxin 
production. One such factor is the signaling molecule c-di-GMP (95, 119).  
 
C-DI-GMP SIGNALING 
 Cyclic bis-(3′ 5′) diguanylate (cyclic diguanylate, c-di-GMP) is a second messenger that 
is produced by nearly all bacteria (120). It was first described in 1987 as a negative regulator of 
cellulose synthesis in Komagataeibacter xylinus. c-di-GMP is a cyclic dinucleotide consisting of 
a 3’ to 5’ linkage of two guanosine monophosphate moieties (121). The c-di-GMP concentration 
within bacterial cells is modulated by enzymes controlling its synthesis and degradation. c-di-
GMP is synthesized from two guanosine triphosphate (GTP) molecules by enzymes containing a 
GGDEF domain known as diguanylate cyclases (120). c-di-GMP is broken down by two distinct 
classes of c-di-GMP phosphodiesterases containing either an EAL or HD-GYP domain (See 
Figure 1.1). Processes regulated by c-di-GMP in bacteria include flagellar motility, 
polysaccharide production, biofilm formation, and virulence factor production (120). c-di-GMP 
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can regulate such processes by binding to protein and RNA-based receptors in the bacterial cell. 
Receptors that have been demonstrated to bind c-di-GMP include a subset of PilZ domain 
containing proteins, certain transcriptional regulators, type IV pilus assembly ATPase proteins, 
and structured RNA regions called c-di-GMP riboswitches (120, 122).  
 PilZ domains are widespread among bacteria and represent the best studied class of 
proteins that bind c-di-GMP (123). The BcsA protein, which controls cellulose synthesis in 
Komagataeibacter xylinus, and the YcgR protein, which controls flagellar motility in 
Escherichia coli, were the first PilZ domain proteins shown to bind c-di-GMP (124). When 
bound to c-di-GMP, YcgR interacts with the FliG and FliM flagellar switch proteins and serves 
to decouple these switch proteins from the motor protein, MotA (125, 126). This has the effect of 
slowing flagellar rotation and biasing the rotation in a single direction, resulting in greatly 
reduced swimming motility by E. coli (126, 127). PilZ domain proteins are widespread among 
bacteria, with many species encoding multiple PilZ domains, though not all PilZ domains bind c-
di-GMP (120, 128, 129). In addition to PilZ domains and riboswitches, there are number of other 
c-di-GMP receptors that function in signaling. These include transcriptional regulators like VpsT 
and VpsR from Vibrio cholerae, MshEN domains usually found in type IV pilus (TFP) assembly 
ATPases, and the recently discovered arginine rich repeat regions of certain CheY family 
proteins (120, 122, 130, 131). 
 There are two classes of riboswitches known to bind c-di-GMP: the GEMM or class I c-
di-GMP riboswitches, and the class II c-di-GMP riboswitches (132, 133). Riboswitches are 
structured RNA elements found in the 5’ untranslated region (UTR) of some mRNAs that 
directly and specifically bind a ligand (134). Riboswitches consist of two parts: an aptamer 
domain responsible for binding the ligand and an expression platform that controls transcription 
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or translation of the downstream RNA. Conformational changes that result from the interaction 
between the ligand and aptamer domain alter the expression platform structure to modulate 
transcriptional read-through or translation initiation (135). Aptamer and expression platform 
regions are often modular such that binding of a ligand to the aptamer can positively or 
negatively regulate gene expression, depending on the linked expression platform (135). 
One mechanism by which riboswitches control gene expression is the modulation of 
transcription termination (132, 134). In an “off” riboswitch of this type, ligand binding promotes 
the formation of a terminator stem loop leading to decreased transcription of downstream genes 
(Figure 1.2) (135). When the transcript is not bound to the ligand, an anti-terminator stem loop is 
formed instead allowing transcription of the downstream genes (134, 135). In an “on” riboswitch 
that regulates transcription termination, binding of the ligand to the riboswitch promotes the 
formation of an anti-terminator stem loop, allowing expression of the downstream genes (135, 
136). When the ligand is absent, formation of a terminator stem loop is favored and transcription 
of the downstream genes is reduced (135, 136). In addition to regulating transcription, 
riboswitches can also regulate translation initiation (135). Regulation of translation typically 
occurs through occlusion of the ribosomal binding site (RBS) within a stem-loop preventing 
ribosomes from binding to the RNA. As for riboswitches that regulate translation, ligand binding 
can either promote or prevent the formation of stem loops that occlude the RBS (134-136).  
Our knowledge of c-di-GMP riboswitches largely relies on the results of in vitro studies 
of ligand binding or testing of riboswitch function in heterologous hosts (132, 133, 135). Only 
two riboswitches have been studied in their native genomic context and organism, both in Vibrio 
cholerae (137, 138). These riboswitches, Vc1 and Vc2, lie upstream of a genes encoding a V. 
cholerae colonization factor, GbpA, and a regulator of the type VI secretion system, TfoY, 
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respectively (137-140). For Vc1, work in our lab showed that Vc1 binds c-di-GMP and that this 
binding positively regulates the expression of gbpA (141). Looking at the riboswitch in isolation 
might lead one to conclude that c-di-GMP positively regulates gbpA expression. However, gbpA 
expression is inhibited in high c-di-GMP conditions through increased expression of a negative 
regulator of gbpA expression, NagC (141). Additionally, low levels of c-di-GMP lead to 
increased expression of gbpA, indicating that in these conditions, the decreased activity of the 
gbpA promoter in high c-di-GMP conditions overrides the positive regulation of gbpA expression 
through the riboswitch (137, 141). For the Vc2 riboswitch, the riboswitch was determined to 
negatively regulate tfoY expression (138). However, high c-di-GMP levels led to increased 
expression of tfoY that was independent of Vc2 (138). These examples suggest that c-di-GMP 
regulation of riboswitch-regulated genes can be very complex and that studying riboswitches in 
their native organism is necessary to properly appreciate the contributions of c-di-GMP 
riboswitches to the overall c-di-GMP regulation of the downstream genes.   
C-DI-GMP SIGNALING IN C. DIFFICILE 
 C. difficile encodes 37 proteins with putative or demonstrated DGC or PDE activity, 
suggesting a complex c-di-GMP signaling network in C. difficile (142). Despite the large number 
of DGCs and PDEs encoded in the genome, C. difficile has few predicted protein receptors. C. 
difficile only encodes a single PilZ domain protein (BcsA) and one MshEN domain protein 
(PilB1) (120). Other potential protein effectors in C. difficile include catalytically inactive DGC 
proteins such as CD630_10280, which is an orthologue of the regulator of biofilm formation 
PssE from Listeria monocytogenes (143). Supplementing its putative protein receptors, C. 
difficile also encodes 16 putative c-di-GMP binding riboswitches. Of these, 12 are GEMM (class 
I) riboswitches and 4 are class II riboswitches (133). Intriguingly, many of the riboswitches are 
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positioned to regulate genes encoding putative cell surface proteins or surface structures (e.g. 
TFP and flagella). This could indicate an important role for c-di-GMP in modification of the C. 
difficile cell surface in response to extracellular stimuli. In C. difficile, c-di-GMP regulates a 
variety of processes including flagellar motility, type IV pilus (TFP) production, biofilm 
formation and surface motility (summarized in Figure 1.1) (119, 144-146). High intracellular 
concentrations of c-di-GMP repress flagellar gene expression and lead to decreased flagellar 
motility in C. difficile (119, 133). The flagellar riboswitch (Cdi-1-3) in C. difficile has been 
shown to bind c-di-GMP and promote transcriptional termination in vitro. Binding of c-di-GMP 
to the aptamer domain of the riboswitch is predicted to induce a conformational change in the 
mRNA, which results in the formation of a terminator stem loop in the expression platform, thus 
preventing transcription of the downstream flagellar genes (132). Thus, the flagellar riboswitch is 
an “off” riboswitch because the ligand-bound conformation promotes termination of 
transcription. 
 High levels of c-di-GMP promote the formation of type IV pili (TFP) in C. difficile (144). 
At high intracellular concentrations of c-di-GMP, C. difficile forms autoaggregates when grown 
in liquid culture (144). Increased intracellular c-di-GMP also promotes motility on agar surfaces 
and the formation of biofilm (119, 146). Autoaggregation, surface motility, and biofilm 
formation in response to high c-di-GMP are dependent on the production of TFP. A c-di-GMP 
riboswitch (Cdi-2-4) is encoded upstream of the pilA1 gene, which encodes a major pilin, serves 
as a positive regulator of pilA1 transcription (144, 145). The conformation of the RNA in the 
absence of c-di-GMP is predicted to favor transcription termination via formation of a terminator 
stem loop (144). Binding of c-di-GMP to the aptamer domain results in a conformational change 
in the RNA that precludes the formation of the terminator stem loop and allows transcription of 
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the pilA1 gene (144). The pilA1 riboswitch of C. difficile is thus an “on” riboswitch in which 
binding of the ligand promotes transcription of downstream genes. Using transcriptional reporter 
fusions of the pilA1 promoter and 5’ UTR to gusA, we showed that increasing intracellular c-di-
GMP stimulated reporter activity (145). However, mutation of conserved riboswitch nucleotides 
predicted to be required for c-di-GMP binding led to decreased reporter activity overall and 
rendered reporter activity unresponsive to increased c-di-GMP. In addition, elevated c-di-GMP 
concentrations also promoted expression of gusA when the pilA1 promoter was replaced with a 
constitutive promoter (145). These results indicate that regulation of TFP gene transcription by c-
di-GMP requires the riboswitch upstream of pilA1 in strain 630Δerm (145).  
 The contributions of TFP, biofilm formation, and surface motility to C. difficile 
pathogenesis are not currently known. Dense communities of bacteria covering the surface of the 
damaged microvilli have been recovered from mice in one model of C. difficile disease, and 
another study showed the formation of biofilm in mice that were mono-associated with C. 
difficile (147, 148). Another group reported that C. difficile binds solely to the mucus layer of the 
intestinal epithelium and they did not observe C. difficile attached to the epithelium in mouse 
infections (149). They did however observe communities of bacteria in the mucus layer, 
indicating that interactions with other bacteria may be important during C. difficile infection 
(149). Studies in the hamster model of C. difficile infection have shown strain-dependent 
differences in localization and interaction with the intestinal epithelium (150, 151). Overall these 
data indicate that C. difficile has the capacity to form biofilm and to interact with the intestinal 
epithelium during infection, but the contributions of these interactions to C. difficile pathogenesis 
is still unclear. The factors that mediate colonization of the intestinal tract by C. difficile remain 
unknown (152). As noted above, c-di-GMP controls the expression of type IV pili and other 
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surface proteins that could potentially serve as colonization factors. In other bacterial species, 
TFP are important for host colonization and contribute to host cell attachment, but the 
contribution of TFP to C. difficile colonization was hitherto unknown. The goals of my thesis 
project were to determine the role of TFP in host cell adherence and colonization of the 
mammalian gut and to expand the known members of the c-di-GMP signaling network in the 
important intestinal pathogen, C. difficile.  
 
FIGURES 
Figure 1.1. c-di-GMP signaling in C. difficile. c-di-GMP (pictured in the center) positively 
regulates TFP production and biofilm formation while negatively regulating flagellar motility 




Figure 1.2 Transcriptional termination controlled by an “off” riboswitch. (A) Ligand 
binding stabilizes stem loop A and promotes formation of a terminator stem loop leading to 
transcript termination. (B) Ligand is unbound favoring the formation of an anti-terminator stem 
loop allowing transcript elongation.
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CHAPTER 2: TYPE IV PILI PROMOTE CLOSTRIDIUM DIFFICILE ADHERENCE 
AND PERSISTENCE IN A MOUSE MODEL OF INFECTION1 
SUMMARY 
 Cyclic diguanylate (c-di-GMP) is a second messenger that regulates the transition from 
motile to sessile lifestyles in numerous bacteria and controls virulence factor production in a 
variety of pathogens. In Clostridium difficile, c-di-GMP negatively regulates flagellum 
biosynthesis and swimming motility, and promotes the production of type IV pili (TFP), biofilm 
formation, and surface motility in vitro. Flagella have been identified as colonization factors 
in C. difficile, but the role of TFP in adherence to host cells and in colonization of the 
mammalian gut is unknown. Here we show that c-di-GMP promotes adherence to epithelial cells 
in vitro, which can be partly attributed to the loss of flagella. Using TFP-null mutants, we 
demonstrate that adherence to epithelial cells is partially mediated by TFP and that this TFP-
mediated adherence requires c-di-GMP regulation. In a mouse model of colonization, the TFP-
null mutants initially colonized the intestine as well as the parental strain, but were cleared more 
quickly. Moreover, compared to the parent strain, C. difficile lacking TFP were particularly 
deficient in association with the cecal mucosa. Together these data indicate that TFP, and their 
                                                          
1 This chapter previously appeared as an article in the journal Infection and Immunity. Figure numbers have been 
modified. The original citation is as follows: McKee RW, Aleksanyan N, Garrett EM, Tamayo R. Infect Immun 2018 
Feb 26. pii: IAI.00943-17. doi: 10.1128/IAI.00943-17. I performed all the experiments with the exception of the 
attachment assays in Figure 2.4, which were performed by Naira Aleksanyan. Liz Garrett assisted me with the 
animal experiments. I wrote the manuscript with edits from my advisor, Rita Tamayo.  
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positive regulation by c-di-GMP, promote attachment of C. difficile to the intestinal epithelium 
and contribute to persistence of C. difficile in the host intestine. 
 
INTRODUCTION 
 Clostridium difficile, recently reclassified as Clostridioides difficile (1), is a spore-
forming, obligate anaerobe responsible for diarrheal diseases resulting in substantial morbidity 
and mortality (1, 2). C. difficile infections (CDI) usually occur following antibiotic therapy, 
however community-associated C. difficile infections in patients without recent antibiotic use are 
increasingly common (3). Moreover, ~20-30 % of CDI patients experience at least one 
recurrence of CDI after cessation of treatment, with additional recurrences becoming 
increasingly likely (4-6). Antibiotic treatment facilitates C. difficile infection by disrupting the 
normally protective microbiota, reducing competition from other bacteria and altering the bile 
salt profile in the gut allowing more efficient germination and outgrowth of C. difficile (7-10). 
Actively growing C. difficile may produce the toxin(s), TcdB and/or TcdA, which glucosylate 
Rho family GTPases in target cells ultimately resulting in the disruption of the intestinal 
epithelium and the characteristic inflammation of CDI (11-13). Despite being essential for 
disease development, TcdA and TcdB are not required for colonization of humans or animal 
models of CDI (14-17). The factors involved in C. difficile colonization and persistence within 
the gut are largely unknown.  
One of the best-studied colonization factors in C. difficile is the flagellum. In the 
epidemic-associated C. difficile strain R20291 (18), a mutation in fliC, which encodes flagellin, 
reduced adherence to Caco-2 epithelial cells in vitro (19). Additionally, fliC mutant bacteria were 
outcompeted by the parental strain in mouse co-infection experiments (19). In strain R20291, a 
 
35 
point mutation in the flagellar motor gene motB, which results in bacteria that produce paralyzed 
flagella, did not influence colonization or attachment to the cecum in mice, indicating that the 
flagellum itself functions in adherence (19). However, in 630Δerm, an erythromycin sensitive 
derivative of C. difficile strain 630 (20), mutations in fliC and fliD increased attachment to Caco-
2 cells, increased virulence in hamster models of infection, and led to a modest defect in mouse 
co-challenge infections with the parental strain (19, 21, 22). These strain specific-phenotypes 
may be attributable to differences in the abilities of R20291 and 630Δerm strains to phase vary 
production of flagella (23-26).   
 Other cell surface proteins have been implicated in adherence to epithelial cells in vitro 
including SlpA, FbpA, and Cwp66 (27-31). While most of these proteins have not been shown to 
alter colonization of C. difficile in animal models, a mutant lacking the putative fructose binding 
protein, FbpA, displayed a modest defect in cecal colonization in a mouse model of C. difficile 
infection (30). Given these data and the lack of severe colonization defects reported for putative 
C. difficile colonization factors, it is likely that adhesion of C. difficile to the intestinal epithelium 
involves multiple, potentially redundant factors. Type IV pili (TFP) are involved in a number of 
bacterial behaviors in other species, including surface attachment, surface-based twitching 
motility, biofilm formation, and cell-cell interactions (32-34). In many Gram-negative pathogens, 
TFP contribute to adherence to both primary and transformed host cell lines (35-38). 
Accordingly, TFP are required for optimal colonization in animal models for a number of 
pathogens, such as Pseudomonas aeruginosa, Vibrio cholerae, Escherichia coli, and others (39-
43). There are a number of mechanisms by which TFP machinery may enhance colonization, 
including direct adhesion to host cells (44), promotion of microcolony formation (45), and 
epithelial cell invasion (46). In Gram-positive bacteria, TFP have not been as well studied. Genes 
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encoding TFP are rare in most Bacilli, but are nearly ubiquitous among Clostridia (47). TFP are 
required for gliding motility in Clostridium perfringens (48). Ectopic expression of a pilin gene 
from C. perfringens in Neisseria gonorrhoeae increased attachment to mouse myoblasts, 
suggesting a role in adherence for TFP in C. perfringens (49).  
TFP genes have been found in every sequenced strain of C. difficile, and a comparative 
phylogenomics analysis of C. difficile indicates that TFP genes are among the set of core genes 
for the species (50, 51). Work from our lab and others revealed that TFP in C. difficile are critical 
for a number of bacterial behaviors, particularly in response to increased levels of the second 
messenger cyclic diguanylate (c-di-GMP) (52-54). In many bacterial species, c-di-GMP 
regulates the switch between motile and non-motile states (55, 56). Likewise in C. difficile, c-di-
GMP negatively regulates flagellar swimming motility and positively regulates TFP biosynthesis 
and TFP-dependent behaviors (52, 53, 57). Regulation occurs via c-di-GMP specific 
riboswitches upstream of the respective flagellum and TFP biosynthetic operons, where the 
flagellar riboswitch is an “off switch” and the TFP riboswitch is an “on switch” (53, 57-59). An 
insertional mutation in the major pilin gene pilA1 or in pilB1, which encodes the pilus assembly 
ATPase, results in bacteria that lack TFP (52, 53, 60). The pilA1 and pilB1 mutants display 
reduced autoaggregation, surface motility, and biofilm formation under conditions of high c-di-
GMP (52, 53). While the contributions of biofilm formation and surface growth to C. difficile 
infection are unclear, bacterial mats have been observed in mouse models of C. difficile infection 
(61, 62).  
Based on the known roles of TFP in host colonization by other pathogens and the 
importance of TFP to autoaggregation and surface behaviors of C. difficile, we hypothesized that 
TFP contribute to host cell attachment and colonization during C. difficile infection. Moreover, 
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we postulated that c-di-GMP positively regulates TFP-mediated interactions with host tissues. In 
this study we found that high c-di-GMP promotes early attachment to a variety of epithelial cell 
types in vitro, and TFP may be important for maintenance of adherence to epithelial cells. Using 
an antibiotic-treated mouse model, we further demonstrated that C. difficile mutants lacking TFP 
initially colonize as well as the parent strain, but are eliminated more quickly from the intestine. 
This study provides evidence that TFP promote adherence of C. difficile to epithelial cells and 
are important for the persistence of C. difficile in the mammalian intestinal tract.  
 
MATERIALS AND METHODS 
Bacterial growth conditions 
 Strains and plasmids used in this study are listed in Table S1. Overnight cultures of C. 
difficile were grown in 2 ml of TY broth (30 g/liter Bacto tryptone, 20 g/liter yeast extract, 1 
g/liter thioglycolate) in an anaerobic chamber (Coy Lab Products) with an atmosphere of 5% H2, 
5% CO2 and 90% N2. For experiments, C. difficile was diluted 1:100 in BHIS (37 g/liter Bacto 
brain heart infusion, 5 g/liter yeast extract) for growth unless otherwise specified. E. coli cultures 
were grown in Luria Bertani medium (Miller) with appropriate antibiotics as needed. Unless 
otherwise specified antibiotics were used at the following concentrations: thiamphenicol (Tm), 
10 μg/ml; chloramphenicol (Cm), 10 μg/ml; ampicillin (Amp), 100 μg/ml; and kanamycin (Kn), 
100 μg/ml. Where appropriate, nisin was added at a final concentration of 1 μg/ml to induce 
transcription from the cpr promoter. 
Construction of pilA1 complementation plasmids 
 To generate pPilA1 (pMC123::PpilA1-RB-pilA1), the promoter, 5’ UTR, and coding 
sequence of pilA1 (CD630_35130) were amplified by PCR from 630Δerm genomic DNA using 
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primers R1183 and R978 (Table S2). This PCR product was digested with EcoRI and PstI, 
ligated into similarly digested pMC123, and transformed into DH5α. To generate pPilA1mut 
(pMC123::PpilA1-RB
A70G-pilA1), we generated a PCR product containing the above fragment 
with an adenine to guanine substitution at position 70 of the riboswitch using splicing by overlap 
extension (SOE). The upstream region of homology was PCR amplified from 630Δerm genomic 
DNA using primers R1183 and R1184, and the downstream region was amplified using primers 
R1185 and R978. The two fragments were spliced together and amplified using R1183 and 
R978, then cloned into pMC123 as above. Clones were confirmed by PCR and sequencing of the 
inserts. These pPilA1 and pPilA1mut plasmids were introduced into the pilA1 mutant via 
conjugation with HB101(pRK24) as described previously (57).  
Attachment Assays 
 HT-29 or Caco-2 human intestinal epithelial cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with fetal bovine serum (FBS) at 10% (HT-29) or 20% 
(Caco-2). Tissue culture-treated 24-well plates (Corning) were seeded with approximately ~105 
cells per well. Tissue culture cells were grown at 37 °C in 5% CO2 for 5-7 days until a confluent 
monolayer was achieved, with fresh media added as needed. To avoid oxygen toxicity to C. 
difficile, prior to inoculation the intestinal cells were transferred to the anaerobic chamber, and 
the medium was removed and replaced with anaerobic DMEM containing the appropriate 
concentration of FBS. For 24 hour attachment assays, Madin-Darby Canine Kidney (MDCK) 
cells grown in DMEM with 10% FBS were seeded into 24 well plates with 105 cells per well. 
Cells were grown at 37 °C for 3 days in 5% CO2 to allow formation of confluent monolayers, 
with fresh media added as needed.  
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C. difficile strains grown overnight (~16 hours) in TY with appropriate antibiotics were 
diluted 1:50 in filter-sterilized BHIS with antibiotics. Nisin was added if necessary for induction 
of gene expression. At mid-exponential phase, the bacteria were diluted 1:10 in DMEM with 
FBS and vortexed. We previously showed that C. difficile does not significantly aggregate at this 
stage of growth (53). Each diluted culture (50 µL) was added to 24-well plates seeded with HT-
29, Caco-2, or MDCK cells and containing 450 μl DMEM with FBS. The plates were sealed 
with tape, removed from the anaerobic chamber, and centrifuged for 10 min at 1000 x g to 
sediment the bacteria onto the tissue culture cells. This centrifugation step was performed 
because c-di-GMP inhibits flagellum biosynthesis and swimming motility, which might 
influence the ability of some strains tested to reach the cell monolayers. The plates were 
transferred back into the anaerobic chamber and incubated at 37 °C for 1 hour (HT-29 and Caco-
2 cells) or 24 hours (MDCK cells). During the incubation, dilutions of the bacterial inoculums 
were plated to enumerate the bacteria added to each well. Following incubation, the medium was 
removed, and the wells were washed 3 times with 1 ml Dulbecco’s phosphate-buffered saline 
(DPBS, Gibco) to remove non-adherent bacteria. After the final wash, the epithelial cells and 
attached bacteria were scraped from the plate and suspended in 500 μl of DPBS by pipetting up 
and down until visible clumps were dispersed. Dilutions were plated on BHIS to enumerate the 
attached bacteria.  
Microscopy 
 HT-29 or MDCK cells were seeded at ~105 cells per cm2 on ThermanoxTm 
(ThermoFisher) coverslips and grown for 5 days (HT-29) or 3 days (MDCK) in DMEM + 10% 
FBS. Bacteria were grown, added to the tissue culture cells and incubated as described above for 
the attachment assays. Following incubation, the monolayers were washed twice with 500 μl 
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PBS to remove unattached bacteria, then fixed by adding 500 μl of ice cold methanol for 5 
minutes. Methanol was removed and samples were then stained with a Gram stain kit (Becton 
Dickinson), mounted on slides, and imaged with an Olympus BX61 v2 microscope at 600X 
magnification.  
Animal Experiments 
 All animal studies were done in compliance with protocols approved by the UNC-CH 
Institutional Animal Care and Use Committee.  
C. difficile spore inoculums were generated by streaking several colonies of C. difficile 
onto 70:30 agar (63) and incubating at 37 °C for 3 days in an anaerobic chamber. The growth 
was suspended in 10 ml DPBS, removed from the anaerobic chamber, and left overnight at room 
temperature to allow for release of mature spores. Spores were purified from the suspensions by 
sucrose gradient as previously described (64). Spores were enumerated by plating serial dilutions 
on BHIS agar containing the germinant 0.1% sodium taurocholate (65).  
Groups of 8-10 week old female C57BL/6 mice were obtained from Charles River 
Laboratories. Beginning 7 days prior to inoculation, the mice were given a cocktail of antibiotics 
in their drinking water, provided ab libitum for 3 days as described previously (66). The 
antibiotics were provided at the following concentrations: kanamycin (400 μg/ml), gentamycin 
(35 μg/ml), colistin (850 units/ml), vancomycin (45 μg/ml), and metronidazole (215 μg/ml) (66). 
Four days prior to inoculation, mice were switched back to regular water for the remainder of the 
experiment. A single intraperitoneal injection of clindamycin (10 μg/g body weight) was 
administered either 24 hours prior to infection (single strain infections) or 48 hours prior to 
infection (competitions). The timing of the clindamycin injection was modified to 48 hours prior 
to inoculation in the competition experiments to ensure that clindamycin concentrations did not 
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favor growth of the mutants, which contain the ermB gene that provides some resistance to 
clindamycin (67, 68). Mice were inoculated with 105 colony forming units (CFU) of C. difficile 
spores (single strain infections) or 2 x 105 total spores (co-infections) by oral gavage. Feces was 
collected in pre-weighed tubes every 24 or 48 hours for 7-14 days, as indicated. 
Fecal samples were weighed following collection, then suspended in 1 ml DPBS by 
vortexing. For single strain infections, serial dilutions of fecal samples were plated on fructose 
agar containing 1 mg/ml sodium taurocholate, 16 μg/ml cefoxitin, and 250 μg/ml cycloserine 
(TCCFA). The burden of spores was calculated as CFU per gram of feces. For competition 
experiments, serial dilutions of fecal samples were plated on TCCFA to enumerate total spore 
burden, as well as TCCFA containing 2 μg/ml erythromycin (for 630Δerm strains) or 20 μg/ml 
lincomycin (for R20291 strains) to enumerate the CFU of mutant bacteria containing the ermB 
resistance gene. To calculate the competitive index (CI), the ratio of mutant to parental bacteria 
for each fecal sample (resistant CFU/[total CFU-resistant CFU])output was divided by the ratio of 
mutant to parental bacteria in the initial spore inoculum (resistant CFU/[total CFU-resistant 
CFU])input. A CI of 1 indicates no difference in bacterial burden, CI <1 indicates that the parental 




c-di-GMP promotes attachment of C. difficile to intestinal epithelial cells.  
 Work from our lab and others recently demonstrated that high intracellular c-di-GMP 
concentrations in C. difficile promote autoaggregation, biofilm formation, and surface motility 
(52, 53, 59). Because c-di-GMP increased both interbacterial interaction and attachment to a 
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surface, we hypothesized that c-di-GMP also promotes attachment to epithelial cells. To test this 
hypothesis, we performed bacterial attachment assays in anaerobic conditions using monolayers 
of HT-29 and Caco-2 human intestinal epithelial cells. We used a previously described strategy 
to artificially increase intracellular concentrations of c-di-GMP in C. difficile, using the nisin-
inducible expression of dccA, which encodes a C. difficile diguanylate cyclase (57). This 
concentration of nisin and level of dccA expression does not substantially inhibit growth, 
particularly at mid-exponential phase when the bacteria were collected (53). C. difficile strains 
grown with or without nisin to induce dccA expression and stimulate c-di-GMP production were 
incubated with HT-29 or Caco-2 cells. Incubations were limited to 1 hour under strict anaerobic 
conditions (required by C. difficile), as the monolayers begin to lose integrity by 4 hours (Figure 
2.1). Expression of dccA in 630Δerm led to a 12- and 96-fold increase in attachment to HT-29 
and Caco-2 cell monolayers, respectively, compared to C. difficile bearing the control vector 
grown with nisin induction (Fig 2.2A, B). In contrast, expression of dccAmut, which encodes a 
catalytically-inactive variant of DccA, did not significantly alter attachment to either cell line. To 
confirm that the C. difficile were associated with the epithelial cells in these assays, we 
visualized the bacteria attached to the epithelial cells using a Gram stain. While the bacteria 
harboring the vector and pDccAmut were sparsely and individually distributed on the surface of 
the epithelial cell monolayers, the bacteria harboring pDccA were present in much higher 
numbers and also clustered together (Figure 2.2C-E). Together these data indicate that c-di-GMP 





Negative regulation of flagellum biosynthesis by c-di-GMP contributes to increased 
attachment to epithelial cells in vitro 
 Dingle et al. previously showed that C. difficile 630Δerm with mutations in fliC or fliD 
encoding flagellin or flagellar cap, respectively, are more adherent to Caco-2 monolayers (21). 
We thus tested whether inhibition of flagellum biosynthesis by c-di-GMP is responsible for the 
increased attachment. We used C. difficile 630Δerm with an intron insertion in sigD, which 
encodes the flagellar sigma factor (69); this mutant was previously shown to lack flagella and 
swimming motility (23, 53, 70). We compared attachment rates of the sigD mutant bearing 
vector alone or complemented with a plasmid containing sigD under the control of a nisin-
inducible cpr promoter to the parental strain bearing vector. Consistent with the previous results 
showing that aflagellate C. difficile are more adherent to tissue culture cells, the 630Δerm sigD 
mutant containing vector alone adhered to HT-29 cells at significantly higher levels than the 
parental vector-bearing strain (Figure 2.3A). Complementation with the sigD gene under the 
control of the nisin-inducible cpr promoter restored adherence to parental levels (Figure 2.2A). 
We next evaluated the effect of increasing c-di-GMP in the absence of flagella by stimulating c-
di-GMP synthesis in the sigD mutant background. Expression of dccA in the sigD mutant strain 
resulted in a further 3.8-fold increase in attachment over the sigD mutant bearing vector or 
expressing the dccAmut allele (Figure 2.3B). This result indicates that additional, sigD-
independent, factors mediate increased adherence to epithelial cells in response to c-di-GMP. 
Type IV pili promote adherence of C. difficile to epithelial cells.  
Because c-di-GMP promotes TFP production, we hypothesized that TFP contribute to the 
observed increase in adherence to epithelial cells. To test this, we examined the ability of 
630Δerm with a mutation in pilA1 (encoding the major pilin) or pilB1 (encoding the pilus 
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biosynthesis ATPase) to adhere to HT-29 and Caco-2 cells. These mutants were previously 
shown to lack the ability to produce TFP under either low or high c-di-GMP conditions, and to 
be deficient in TFP-dependent behaviors (52, 53). The pilA1 and pilB1 mutants showed 
somewhat reduced adherence to HT-29 cells compared to the parental strain, but the differences 
were not statistically significant (Figure 2.4A). C. difficile with basal c-di-GMP levels produce 
relatively low numbers of TFP during growth in BHIS medium (53). We reasoned that 
increasing intracellular c-di-GMP by over-expressing dccA, which stimulates TFP biosynthesis 
(53), might reveal a role for TFP. However, elevating c-di-GMP augmented adherence equally in 
the parental and TFP-null strains (Figure 2.4B).  
 While 1-hour adherence assays effectively measure the initial attachment of the bacteria 
to the epithelial cells, the relatively short incubation may miss factors that are important for 
maintained adherence or expansion of the attached bacteria. Indeed, many experiments 
evaluating bacterial adherence to epithelial cells use longer co-incubation periods such as 24 
hours (71, 72). However, Caco-2 and HT-29 cell monolayers lose integrity after prolonged 
incubation under the strict anaerobic conditions required by C. difficile (Fig 2.1). To assess 
adherence of C. difficile to epithelial cells over a longer time frame, we decided to use another 
epithelial cell line that is more tolerant of anaerobic conditions, Madin-Darby canine kidney 
(MDCK) epithelial cells (73). Whereas monolayers of either Caco-2 or HT-29 cells were 
substantially disrupted after as few as 4 hours in the anaerobic chamber, MDCK cells maintained 
their monolayers after 24 hours of incubation in the anaerobic chamber (Figure 2.1). As with 
HT-29 and Caco-2 cells, TFP were dispensable for attachment to MDCK cells at 1 hour (Figure 
2.5A). After 24 hours incubation, the C. difficile pilA1 and pilB1 mutants showed significantly 
reduced attachment to MDCK cells (Figure 2.5B). Growth of pilA1 and pilB1 mutant bacteria 
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was equivalent to the parental strain in DMEM + 10% FBS (Figure 2.6). The mutations also did 
not affect flagellum-based swimming motility (Figure 2.7).  
To confirm that the reduced attachment to MDCK cells was due to the lack of TFP, we 
complemented the pilA1 mutation by ectopic expression of pilA1. For expression of pilA1, we 
used the native promoter and leader sequence (5’ untranslated region, UTR) containing the c-di-
GMP sensing riboswitch. Ectopic expression of pilA1 from its native promoter (pPilA1) partially 
restored attachment of the mutant bacteria to near that of the parental strain (Figure 2.5C). 
Incomplete complementation is likely due to polar effects of the intron insertion on the 
downstream TFP biosynthesis genes (53). However, expression of pilA1 under the control of the 
riboswitch containing a mutation (A70G) rendering it unable to bind and sense c-di-GMP (53) 
did not complement the effect of the pilA mutation on adherence to MDCK cells (Figure 2.5C, 
pPilA1mut). Together these data indicate that TFP contribute to host cell colonization at later time 
points, and sensing of c-di-GMP by the riboswitch is important in this process.  
Type IV pili are dispensable at early stages of infection but are important for persistence in 
the host intestine 
 In many bacterial pathogens, TFP play a role in colonization of the host and/or virulence 
(74). We therefore examined the contribution of TFP to the ability of C. difficile to colonize and 
cause disease in an antibiotic-treated mouse model of CDI (66). After treatment with a cocktail 
of antibiotics, C57BL/6 mice were inoculated by oral gavage with 105 spores of the 630Δerm 
parental strain, the pilA1 mutant, or the pilB1 mutant. The intestinal burden of C. difficile was 
monitored by collecting feces from the mice daily and enumerating colonies on TCCFA, a 
medium that allows outgrowth of C. difficile spores while inhibiting the growth of other bacteria 
(75). The numbers of spores recovered from the feces of mice infected with a mutant or parent 
 
46 
strain were similar for the first 3 days of the infection, suggesting that TFP are dispensable for 
initial colonization of the mouse large intestine (Figure 2.8). By days 4 and 5, mice infected with 
the pilB1 mutant showed a modest but statistically significant decline in CFU compared to those 
infected with 630Δerm bacteria. Both the pilA1 and pilB1 mutant-infected animals shed fewer 
CFU in feces on day 6, although the differences did not reach statistical significance due to high 
variability among mice infected with the pilA1 or pilB1 mutants. On day 7, spore counts for the 
TFP mutant infections were below the limit of detection in all mice, while all but one mouse 
infected with 630Δerm were still shedding spores above the limit of detection (Fig 2.8). An 
independent mouse colonization experiment yielded similar results, but with slight changes in 
the timing of the decline in bacterial burden.  
 To control for variation between mice and to better capture subtle difference between 
strains, we performed co-infections with 630Δerm and either the pilA1 or pilB1 mutants. The 
ermB gene used to generate the pilA1 and pilB1 mutations allowed differentiation between the 
Erm-resistant mutants and Erm-sensitive parent strain. A competition between the parent strain 
and a tcdR mutant, which expresses the glucosylating toxin genes at significantly lower levels 
(69, 76) but should be competent for colonization (14, 15, 17), was included as a control. On day 
1 post-inoculation, the competition indices (CI) were ~1, indicating an equal ability to establish 
colonization. Throughout the 14 day experiment, the pilA1 mutant was usually present in feces at 
numbers comparable to the parent strain; the exceptions are days 7 and 9, when significantly 
fewer pilA1 mutant bacteria were recovered (Figure 2.9A). In contrast, the pilB1 mutant showed 
attenuated colonization after day 1, with CI’s significantly less than 1 on days 3, 5, 7, 9, and 13 
(Figure 2.9B). The control experiment using the tcdR mutant yielded CI’s equal to or somewhat 
greater than 1 (Figure 2.9C), indicating that TcdR is dispensable for colonization in the mouse 
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model, and that the presence of the ermB cassette is not responsible for the fitness defect of the 
mutants.  
 To ensure that the observed defects in colonization for the TFP-null mutants are not 
specific to the 630Δerm background, we also examined the contribution of TFP to colonization 
and persistence in an epidemic-associated strain of C. difficile, the ribotype 027 strain R20291 
(18). When inoculated as a co-infection with the parental strain, the R20291 pilB1 mutant was 
initially recovered from feces in numbers comparable to the parental strain, but was outcompeted 
by the parental strain on days 3 and 5 post-inoculation (Figure 2.10). These data indicate that 
TFP are dispensable for initial establishment of colonization by multiple strains of C. difficile, 
but support a role for TFP in maintaining colonization of the mouse intestine.  
Type IV pili promote association of C. difficile with the cecal epithelium 
 We hypothesized that TFP enhance intestinal colonization by promoting attachment of 
the bacteria to the intestinal epithelium as observed in vitro. To test this, we compared the ratios 
of TFP-null and parent strain bacteria associated with the cecal mucosa and present in the lumen. 
Mice were co-inoculated with the pilB1 mutant and 630Δerm strains, and ceca were harvested at 
day 3, when the mutant first showed decreased recovery from feces (Figure 2.9B). The luminal 
fraction consisted of the cecal contents combined with the contents of a single PBS-wash. The 
remaining cecal tissue comprised the tissue-associated fraction. Homogenates of each fraction 
were plated on selective media and the CI’s were calculated separately. In the cecal lumen, the 
pilB1 mutant bacteria were recovered at a lower rate (geometric mean of CI = 0.27), but in the 
tissue-associated fraction the CI was significantly lower (geometric mean of CI = 0.12) (Figure 
2.11). These data indicate that the pilB1 mutant bacteria are less likely to be found in close 
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association with the epithelium, which may explain the defect in maintenance of colonization in 
the dual-strain infections and the lack of persistence in single-strain infections. 
 
DISCUSSION 
 The mechanism by which C. difficile colonizes the host intestine is poorly understood, 
though multiple cell surface proteins and structures have been explored as possible adhesins. In 
C. difficile, c-di-GMP regulates the transition between motile and surface-associated states in 
part by negatively regulating flagellar gene expression, and positively regulating TFP gene 
expression (52, 53). This study evaluated the contributions of c-di-GMP, flagella, and TFP to the 
ability of C. difficile to adhere to intestinal epithelial cells and the role of TFP in host 
colonization.  
While previous work demonstrated a role for c-di-GMP in biofilm formation and 
autoaggregation of C. difficile, the effects of c-di-GMP signaling on the interaction between C. 
difficile and host cells had not been explored. In vitro adherence assays demonstrated that the 
second messenger c-di-GMP promotes attachment of C. difficile to HT-29 and Caco-2 colonic 
epithelial cells. Inhibition of flagellum biosynthesis by c-di-GMP is partially responsible for 
increased attachment, consistent with previous studies investigating the roles of flagellar proteins 
in C. difficile adherence (19, 21). It is possible that the presence of peritrichous flagella on the 
surface of C. difficile sterically interfere with the ability of adhesins on the bacterial surface to 
interact with the epithelial cells. In addition to removing the steric hindrance of the flagella, c-di-
GMP may promote the presentation of other adhesins on the bacterial surface. Increasing 
intracellular c-di-GMP in a sigD mutant background led to a further increase in attachment, 
indicating that c-di-GMP regulates additional factors involved in attachment to epithelial cells. 
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We hypothesized that TFP, which are positively regulated by c-di-GMP, function in this 
capacity. Our in vitro data indicate that TFP are not required for early attachment to epithelial 
cells, but contribute to optimal prolonged adherence. Other putative adhesins regulated by c-di-
GMP, such as CD2831 and CD3246, could promote early attachment of C. difficile to host cells 
(77, 78).  
Our data also indicate that c-di-GMP signaling is required for promoting adherence by 
TFP. Restoration of adherence in the pilA1 mutant required a functional c-di-GMP riboswitch 
controlling pilA1 expression. Thus, c-di-GMP levels are high enough to support TFP production 
in these experiments. There is evidence that the interaction of C. difficile with a surface leads to 
increased intracellular c-di-GMP levels (52), and stimulation of c-di-GMP production may occur 
during interactions with host cells as well. c-di-GMP may also post-translationally regulate TFP 
biosynthesis in C. difficile. Some TFP are associated with PilB ATPases containing a MshEN 
domain that binds c-di-GMP (79, 80). This c-di-GMP binding motif is conserved in the C. 
difficile MshE orthologue, PilB1, and potentially contributes to the positive regulation of TFP in 
C. difficile as was recently shown for C. perfringens PilB2 (81). Future work will examine the 
potential roles of two distinct mechanisms of TFP regulation by c-di-GMP. 
In a mouse model of CDI, both pilA1 and pilB1 mutant bacteria were deficient in long-
term colonization of the intestine. The defect was more pronounced for the pilB1 mutant, 
suggesting that alternative pilins in addition to PilA1 are important for C. difficile persistence. 
The decreased recovery of the pilB1 mutant in the tissue-associated fraction of the cecum 
suggests a role for TFP in promoting close association with the intestinal epithelium. We 
speculate C. difficile bacteria embedded more deeply in the mucus and/or in direct contact with 
epithelial cells are less likely to be excreted, serving as a reservoir for persistence and disease 
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recurrence. While the importance of autoaggregation, microcolony formation, and biofilm 
development in the host for C. difficile disease development is unclear, mats of C. difficile have 
been observed associated with the intestinal epithelium of C. difficile mono-associated mice (61, 
62), and in mucus-associated mixed-species communities in the cecum and colon (82). Given 
their role in autoaggregation of C. difficile, TFP may facilitate or stabilize formation of single or 
multispecies microcolonies, and ultimately biofilms, on the epithelium, rather than function as 
adhesins per se. 
 Cell monolayers in general are not representative of the diverse range of cell types and 
structures found in the intestinal mucosa. Several groups have been working toward producing 
more physiologically relevant tissue culture models of the intestine that could improve the 
understanding of C. difficile interactions with host cells (83-86). For example, organoids and 
enteroids grown from primary stem or progenitor cells preserve some of the structure of 
intestinal villi and are also made up of a diverse array of cell types, unlike monocultures of 
transformed cell lines. While valuable for studying the disruption of the epithelial cell barrier by 
C. difficile toxins (87), these models may not be not ideal for studying putative colonization 
factors because these are closed systems. Models using differentiated stem cells grown on 
scaffolds could allow for co-culture of C. difficile and epithelial cells by allowing oxygenation of 
the host cells at the basolateral surface while preserving an anaerobic environment in the apical 
space (86). Improvements to these models will allow for a much better understanding of 
intestinal colonization and host interaction of C. difficile and other anaerobes. Factors that 
influence C. difficile colonization and persistence may prove valuable in improving the treatment 
and prevention of CDI, especially in light of the high recurrence rate among patients treated for 





Figure 2.1. Viability of epithelial cell lines under anaerobic conditions.  Monolayers of Caco-
2, HT-29, and MDCK cells before and after incubation in anaerobic conditions for 1, 4 and 24 




Figure 2.2. c-di-GMP promotes C. difficile attachment to epithelial cell monolayers in vitro.  
 C. difficile strain 630Δerm containing vector (pMC-Pcpr), pDccA, or pDccAmut were grown to 
mid-log phase in BHIS with 10 μg/ml thiamphenicol to maintain the plasmids and 1 μg/ml nisin 
to induce expression as indicated. Bacteria were added to HT-29 (A) or Caco-2 (B) epithelial cell 
monolayers, centrifuged briefly, and incubated for 1 hour. Serial dilutions of bacterial inoculums 
and outputs were plated and CFU enumerated to determine the percent of bacteria that remained 
attached. The means and standard deviations of 3 biological replicates are shown. Data were 
analyzed using one way analysis of variance (ANOVA) and Tukey’s post-test. ** P < 0.01, *** 
P < 0.001. (C-E) C. difficile containing the indicated plasmids was grown to mid-log phase as 
above and added to HT-29 cell monolayers grown on coverslips. After 1 hour incubation, 
coverslips were rinsed with PBS and stained with crystal violet and safranin counterstain. C. 
difficile are stained dark purple (indicated by white arrows), and the HT-29 cell monolayers are 






Figure 2.3. Aflagellate C. difficile adhere better to HT-29 cell monolayers.  C. difficile 
cultures were grown to mid-exponential phase in BHIS with 10 μg/ml thiamphenicol and 1 
μg/ml nisin to induce gene expression as indicated. Bacteria were added to HT-29 epithelial cell 
monolayers, centrifuged briefly, and incubated for 1 hour. Serial dilutions of bacterial inoculums 
and outputs were plated to enumerate CFU and determine the percent of bacteria that remained 
attached. (A) Mutation of sigD increases attachment to HT-29 cells. (B) Increasing c-di-GMP in 
the sigD mutant further promotes attachment to HT-29 cells. Strain background and plasmids are 
indicated. The means and standard deviations of 3 biological replicates are shown. Data were 






Figure 2.4. Attachment to HT-29 cell monolayers at 1 hour is not dependent on type IV pili. 
Mid-exponential phase cultures of C. difficile 630Δerm, pilA1 mutant, or pilB1 mutant were 
added to HT-29 epithelial cell monolayers, centrifuged briefly, and incubated for 1 hour. Serial 
dilutions of bacterial inoculums and outputs were plated and enumerated to determine the 
percent of bacteria that remained attached. (A) Attachment of 630Δerm and TFP-null mutants to 
HT-29 cells. (B) Attachment of 630Δerm and TFP-null mutants containing pDccA, grown in the 
presence or absence of 1 μg/ml nisin, to HT-29 cells. Shown are the means and standard 
deviations from 3 biological replicates. No statistically significant differences were observed 





Figure 2.5. Type IV pili promote adherence to MDCK cell monolayers at 24 hrs.  
Attachment of 630Δerm and TFP-null mutants after 1 hour (A) or 24 hours (B) incubation with 
MDCK cell monolayers. In (A) data are expressed as the percent of the original inoculum 
recovered following incubation and PBS washes, with 3 biological replicates for each strain. In 
(B) data are expressed as the total CFU recovered per well after 24 hours incubation, with 6 
biological replicates. Data were analyzed using a one way ANOVA with Dunnett’s test for 
multiple comparisons. (C) Complementation of the adherence defect of the pilA1 mutant after 24 
hours incubation with MDCK cell monolayers. Symbols represent values from individual 
animals, and error bars indicate the standard deviations. Data were analyzed by one way 
ANOVA using the Holm-Sidak method to correct for multiple comparisons. * P < 0.05, ** P < 





Figure 2.6. Growth of C. difficile strains in DMEM culture medium.  630Δerm, the pilA1 
mutant, and pilB1 mutant were grown in DMEM + 10% FBS without phenol red, with OD600 





Figure 2.7. Swimming motility of 630Δerm and TFP mutants.  Bacteria from individual 
colonies were inoculated into soft agar plates containing 0.5X BHIS and 0.3% agar and 
incubated at 37 oC under anaerobic conditions for 48 hours. Shown are the means and standard 
deviations of the diameters of the colony swarms from 4 biological replicates. Data were 





Figure 2.8. Single strain mouse infections of 630Δerm, pilA1 mutant and pilB1 mutant.  
Mice that had been pretreated with antibiotics were inoculated with 105 spores. Feces were 
collected daily and serial dilutions were plated on C. difficile selective media with spore 
germinant (TCCFA) to monitor the burden of C. difficile. Symbols represent values from 
individual animals. Data were analyzed by two way ANOVA using the Holm-Sidak method to 





Figure 2.9. C. difficile pilus mutants are outcompeted by the parental strain in murine co-
infections.  Mice were inoculated with mixed inoculums containing ~105 spores of each strain. 
Feces was collected every 2 days starting 1 day post-inoculation and plated on TCCFA (total 
spores) and TCCFA with erythromycin (mutant spores only) to determine bacterial burden. 
Competitive indices (mutant:parent) for the competition between (A) 630Δerm and pilA1 mutant, 
(B) 630Δerm and pilB1 mutant, and (C) 630Δerm and tcdR mutant. Data were excluded if fewer 
than 10 total spores were recovered. Symbols represent CI values from individual animals, and 
error bars indicate the standard deviations. Data were analyzed by Wilcoxon rank sum test 






Figure 2.10. Competition of R20291 and R20291 pilB1::ermB strains in the mouse model.  
R20291 pilB1::ermB versus the R20291 parent strain were co-inoculated into antibiotic-treated 
C57BL/6 mice. CFU recovered from feces were used as a proxy for bacterial load in the 
intestine. Fecal samples were collected and homogenized at the indicated times post-inoculation 
and plated on TCCFA and TCCFA supplemented with lincomycin at 20 μg/ml to enumerate total 
CFU and mutant CFU, respectively. Competitive indices (CI) were calculated as detailed in the 
Materials and Methods. Symbols reflect CI from individual mice, bars indicate standard 





Figure 2.11. TFP promote association of C. difficile with the cecal epithelium.  Mice were 
co-inoculated with ~105 spores each of the 630Δerm and pilB1 mutant. Ceca were harvested 
anaerobically at day 3 post-inoculation. Cecal contents and a 1 ml wash of PBS were combined 
into the lumenal fraction. The tissue-associated fraction was obtained by homogenizing the 
remaining cecum. Serial dilutions of the lumenal and tissue-associated fractions were plated on 
TCCFA (total C. difficile) and TCCFA with erythromycin (mutant C. difficile) to determine the 
bacterial burden of each strain. Symbols represent CI (mutant:parent) values from individual 
animals, and error bars indicate the standard deviations. Data were analyzed by Wilcoxon rank 



















Table 2.2. Strains and plasmids used in this study. 
Strain/Plasmid Description/Purpose Reference 
Plasmids   
pMC123 E. coli – C. difficile shuttle vector; AmpR, CmR/TmR [88] 
pMC-Pcpr pMC123 with cpr promoter in the multiple cloning site [89] 
pDccA pMC-Pcpr ::dccA (CD630_14200) [89] 
pDccAmut pMC-Pcpr ::dccAmut (AADEF) [89] 
pSigD pMC-Pcpr ::sigD (CD630_02660)  [90] 
pPilA1 pilA1 complementation plasmid with native promoter and riboswitch, 
pMC-PpilA1-RB-pilA1 (CD630_3513), abbreviated as pPilA1 
This study 
pPilA1mut pilA1 complementation plasmid with native promoter and riboswitch 
unable to bind c-di-GMP, pMC-PpilA1-RBA70G-pilA1, abbreviated as 
pPilA1mut 
This study 
   
E. coli strains   
DH5α F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17(rκ -, mκ+) phoA supE44 thi-1 gyrA96 relA1 λ- tonA 
Invitrogen 
[91] 
HB101 F− mcrB mrr hsdS20(rB− mB−) recA13 leuB6 ara-14 proA2 lacY1 
galK2 xyl-5 mtl-1 rpsL20 
[92] 
RT1026 HB101(pRK24) pPilA1 This study 
RT1027 HB101(pRK24) pPilA1mut This study 
   
C. difficile strains   
630Δerm Ribotype 012, erythromycin-sensitive derivative of C. difficile 630 [93] 
R20291 Ribotype 027, epidemic isolate [94] 
RT761 630Δerm pilA1::ermB  [90] 
RT762 630Δerm pMC-Pcpr [90] 
RT763 630Δerm pDccA [90] 
RT764 630Δerm pDccAmut [90] 
RT765 630Δerm pilB1::ermB, pMC-Pcpr [90] 
RT766 630Δerm pilB1::ermB, pDccA [90] 
RT767 630Δerm pilB1::ermB, pDccAmut [90] 
RT768 630Δerm pilA1::ermB, pMC-Pcpr [90] 
RT769 630Δerm pilA1::ermB, pDccA [90] 
RT770 630Δerm pilA1::ermB, pDccAmut [90] 
RT1075 630Δerm sigD::ermB  [90] 
RT1138 630Δerm sigD::ermB pSigD This study 
RT1136 630Δerm sigD::ermB pMC-Pcpr [90] 
RT1265 630Δerm sigD::ermB pDccA This study 
RT1266 630Δerm sigD::ermB pDccAmut This study 
RT1362 630Δerm pilA1::ermB pPilA1 This study 
RT1366 630Δerm pilA1::ermB pPilA1mut  This study 
   
Eukaryotic cell lines   
Caco-2 Caco-2 (ATCC® HTB-37) human colorectal adenocarcinoma cells [95] 
HT-29 HT-29 (ATCC® HTB-38) human colorectal adenocarcinoma cells [96] 
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CHAPTER 3: TRANSCRIPTIONAL REGULATION IN C. DIFFICILE BY THE 
SECOND MESSENGER C-DI-GMP2 
SUMMARY 
 Cyclic diguanylate (c-di-GMP) is a signaling molecule that regulates an array of 
processes in bacteria, primarily the switch between motile and non-motile lifestyles. The 
pathogen C. difficile encodes 37 proteins known or predicted to be involved in c-di-GMP 
metabolism and 16 putative c-di-GMP binding riboswitches. Recent work has shown that c-di-
GMP signaling controls C. difficile swimming motility, biofilm formation, surface motility, and 
persistence in mouse infections. However, knowledge of the number genes and proteins that are 
targets of c-di-GMP regulation in this bacterium is limited. Here, we determine the 
transcriptional regulon of c-di-GMP in C. difficile and demonstrate that c-di-GMP controls the 
production of putative cell surface proteins that promote biofilm formation. We also demonstrate 
that a number of genes in C. difficile are regulated via c-di-GMP sensing riboswitches and that 
moderate changes in intracellular c-di-GMP can have large effects on their expression.  
 
INTRODUCTION 
 Cyclic diguanylate (c-di-GMP) is a second messenger that is nearly ubiquitous in bacteria 
(1). First discovered as a promoter of cellulose production in Komagataeibacter xylinus, c-di-
                                                          
2 I performed all experiments in this chapter with the exception of the alkaline phosphatase assays, which were 
performed by Carissa Harvest. I wrote this section with revisions provided my advisor, Rita Tamayo  
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GMP is now known to regulate a variety of intracellular processes in diverse bacterial species (1-
3). These processes include the transition between motile and sessile lifestyles, cell cycle control, 
and in some cases virulence factor production (4-10). c-di-GMP is synthesized by diguanylate 
cyclases (DGCs) and broken down by c-di-GMP phosphodiesterases (PDEs). The concentration 
of c-di-GMP is controlled by regulating the production of these proteins and/or by regulating 
their enzymatic activity. Many bacteria encode multiple DGCs and PDEs leading to very 
complex c-di-GMP signaling networks (11).  
c-di-GMP acts by binding to targets within the bacterial cell. Proteins that bind c-di-GMP 
include proteins containing PilZ domains, diguanylate cyclases containing I-sites, MshEN 
domains and the Cle subfamily of CheY proteins (12-15). c-di-GMP can also bind to certain 
transcription factors and alter their activity (16-18). In addition to these protein receptors, c-di-
GMP can bind to two distinct RNA structures, the GEMM (class I) and class II c-di-GMP 
riboswitches, to carry out its regulatory function (19, 20). Riboswitches are usually found in the 
5’ untranslated region (UTR) of transcripts (21). Binding of a ligand to the riboswitch alters the 
secondary structure of the RNA. These structural changes promote or inhibit transcript 
termination, mRNA stability, or translation initiation (21, 22). Much of the work on c-di-GMP 
riboswitches has been performed using purified c-di-GMP and transcripts generated through in 
vitro transcription (19, 23). However, little work has been done to directly test the role of c-di-
GMP riboswitches in their native genetic contexts in vivo.  
 The bacterial pathogen Clostridioides difficile (formerly Clostridium difficile) is an 
obligate anaerobe that causes hundreds of thousands of infections each year in the United States, 
resulting in an estimated 44,000 deaths in 2014 (24, 25). Despite the severity of the public health 
threat, little is known about the factors that allow C. difficile to colonize and persist in the 
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intestine. We recently determined that type IV pili (TFP) promote persistence of C difficile in the 
mammalian intestine (26). The production of TFP is positively regulated by c-di-GMP (27). 
Additionally, c-di-GMP negatively regulates production of a C. difficile colonization factor, the 
flagellum (28, 29). Because of the importance of c-di-GMP in the regulation of these two surface 
structures involved in colonization and persistence, we surmised that additional c-di-GMP 
regulated factors could be important for C. difficile pathogenesis.  
  C. difficile strain 630 encodes 37 proteins with putative or demonstrated DGC or PDE 
activity (28, 30, 31). Additionally, the C. difficile 630 genome encodes 16 predicted GEMM and 
class II c-di-GMP sensing riboswitches, more than any sequenced bacterial genome outside of a 
few delta-proteobacteria, suggesting an important role for c-di-GMP signaling through 
riboswitches in this organism (3, 19, 20). Previous work demonstrated that in C. difficile c-di-
GMP modulates flagellum biosynthesis and swimming motility, toxin production, type IV pilus 
(TFP) production, TFP-dependent surface motility, and biofilm formation (27, 28, 32, 33). 
Transcription of the flagellar genes and the genes for TFP production is under the control of c-di-
GMP sensing riboswitches (19, 27, 33). For the flagellar operon, c-di-GMP binding to the Cdi-1-
3 riboswitch in the 5’ UTR of the flgB operon mRNA promotes transcript termination, leading to 
a decrease in the transcription of flgB and other genes in the early-stage flagellar operon (19, 28). 
Because the early-stage flagellar operon encodes SigD, a positive regulator of C. difficile toxin 
gene transcription, c-di-GMP negatively regulates toxin production as well (10). In contrast, the 
Cdi-2-4 riboswitch in the 5’ UTR of the pilA1 transcript forms a terminator stem-loop in the 
absence of c-di-GMP (27). Upon binding to c-di-GMP, the Cdi-2-4 riboswitch undergoes a 
change in secondary structure resulting in transcription read-through and expression of the 
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downstream genes (27). Accordingly, c-di-GMP positively regulates pilus gene expression and 
TFP production in vivo (27, 33).  
Using transcriptional fusions to a reporter gene, we showed that the Cdi-2-4 riboswitch 
controls gene expression in response to c-di-GMP in two strains of C. difficile, 630Δerm and 
R20291 (33).  In vivo studies of GEMM riboswitches in Vibrio cholerae showed that c-di-GMP 
regulates expression of genes adjacent to the two riboswitches, Vc1 and Vc2, but these studies 
also showed that the promoters of these genes, gbpA and tfoY, were regulated by c-di-GMP 
concentrations as well (34, 35). Moreover, for these two genes, transcriptional control of the 
promoter and post-transcriptional regulation via c-di-GMP binding to the riboswitch were in 
opposing directions (34, 36). These studies indicate that c-di-GMP can regulate the expression of 
a gene through multiple, sometimes opposing mechanisms. The observations from the in vivo 
analysis of riboswitches demonstrate that while in vitro transcription can be used to measure 
interactions between c-di-GMP and nascent mRNA, these interactions need to be placed in the 
appropriate biological context before making conclusions about the regulation of expression in 
vivo.  
Some of the phenotypic changes that are induced by high levels of intracellular c-di-GMP 
can be attributed at least partially to regulation of TFP and flagellar biosynthesis (26-28, 33). 
Biofilm formation and autoaggregation of C. difficile, for example, are both decreased in mutants 
that lack TFP, yet high intracellular c-di-GMP levels still promote biofilm formation and 
autoaggregation in these pilus-deficient strains (27, 33). Initial attachment of C. difficile to 
epithelial cells in vitro is enhanced in bacteria that lack flagella and also in bacteria with high c-
di-GMP (26, 37). These results suggest that negative regulation of flagella contributes to the 
enhanced attachment of bacteria with high intracellular c-di-GMP levels. However, increasing 
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the c-di-GMP concentration in a sigD mutant, which lacks flagella, further augmented adherence 
to epithelial cells, indicating that the flagellar regulation alone did not account for the difference 
in attachment levels in high c-di-GMP conditions (26). These data indicate that c-di-GMP 
regulates additional factors that contribute to autoaggregation, biofilm formation, and attachment 
to epithelial cells.  
 To identify additional factors regulated by c-di-GMP in C. difficile, we compared the 
transcriptomes of C. difficile strain 630erm with elevated intracellular c-di-GMP concentrations 
and basal c-di-GMP levels. We identified a large number of genes that are known or predicted to 
be involved in motility or adherence to surfaces, consistent with a role for c-di-GMP in 
controlling the switch between motile and non-motile states. We further examined the roles of 
several c-di-GMP regulated cell envelope proteins in biofilm formation. All eleven genes with c-
di-GMP riboswitches encoded upstream were regulated by c-di-GMP. We used transcriptional 
reporters coupled with qRT-PCR analysis to quantify changes in the transcription of these 
riboswitch-adjacent genes over a broad range of c-di-GMP levels, and show that moderate 
changes in c-di-GMP levels can have large effects on the transcription of some of these genes. 
The c-di-GMP regulation of some of these genes occurs through the promoter in addition to 
regulation through the riboswitch.  
 
RESULTS 
c-di-GMP controls the transcription of a large number of genes in C. difficile  
 Recent work has shown that c-di-GMP controls a number of processes in C. difficile 
including flagellar motility, biofilm formation, surface motility, and adherence to epithelial cells 
(26-28, 32, 33). Transcriptional regulation of genes encoding flagellar and TFP proteins by c-di-
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GMP accounts for only a portion of these phenotypic changes (26, 27, 33). In addition C. difficile 
harbors a large number of proteins involved in c-di-GMP metabolism and 16 predicted c-di-
GMP riboswitches. We used RNA-seq to profile the transcriptomes of C. difficile 630Δerm with 
basal or elevated c-di-GMP. To increase intracellular c-di-GMP, we used our previously 
described approach involving ectopic, nisin-inducible expression of a C. difficile diguanylate 
cyclase gene, dccA (28). C. difficile 630Δerm bearing the pDccA plasmid or vector control were 
grown to mid-exponential phase with 1 μg/ml nisin to induce expression of dccA. RNA was 
processed for sequencing using an Illumina Hiseq-2500. Reads were mapped to the CD630 
genome (AM180355) and normalized by RPKM (Reads mapped per kilobase per million reads). 
Genes regulated by c-di-GMP were identified using the following criteria: changes in RPKM >2-
fold between the two conditions and a Bonferoni-corrected p-value of <0.05 after differential 
expression analysis. A complete list of the significantly-regulated genes is found in Table A1.1 
in APPENDIX 1. These genes were grouped according to the predicted Riley functional class of 
their encoded proteins (38, 39) (Fig 3.1A).  
 A total of 166 genes met the criteria, with 120 genes being negatively regulated and 46 
being positively regulated by c-di-GMP (Figure 3.1B). The largest class of genes regulated by c-
di-GMP were genes involved in chemotaxis and flagellar motility (37 total genes). These genes 
account for nearly 25% of the c-di-GMP regulated genes we identified. Consistent with previous 
work showing that c-di-GMP negatively regulates flagellar motility, all these genes showed 
decreased expression in the pDccA (high c-di-GMP) strain (Fig 3.1B). The next largest set of c-
di-GMP regulated genes consist of genes encoding proteins that are known or predicted to 
localize to the cell envelope. Among this set of gene products are proteins involved in 
biosynthesis of TFP as well as three putative surface proteins that are predicted to be controlled 
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by c-di-GMP riboswitches (CD630_27970, CD630_28310 and CD630_32460). The third major 
class of c-di-GMP regulated genes encode proteins predicted to be involved in transport/binding. 
Of these, seven are predicted PTS system proteins that are likely involved in importing sugars or 
sugar alcohols. Several of the remaining genes are predicted to encode phage proteins, proteins 
involved in the transfer of mobile genetic elements, and proteins involved in iron regulation (e.g. 
FeoB1) or oxidative stress (e.g. Rbr1 and TrxA1).  
 
Ectopic expression of c-di-GMP regulated cell envelope proteins promotes biofilm 
formation 
 Because several of the genes regulated by c-di-GMP encoded putative cell envelope 
proteins, we speculated that these proteins play a role in biofilm formation, a process that is 
promoted by c-di-GMP in C. difficile (33, 40). The fold changes in transcript levels for these six 
genes under elevated c-di-GMP conditions, based on the RNA-seq analysis, are listed in Table 
3.1. To determine their effects on biofilm formation, genes encoding the individual cell envelope 
proteins were ectopically expressed in C. difficile from an ATc-inducible promoter (Ptet). Four of 
the six genes (CD630_27950, CD630_27960, CD630_27970, and CD630_3246) significantly 
increased biofilm formation compared to the vector control indicating a potential role for those 
proteins in biofilm formation (Fig 3.2). 
 
Genes downstream of predicted c-di-GMP riboswitches are regulated by c-di-GMP in a 
dose-dependent manner 
 We observed transcriptional regulation of many genes with predicted c-di-GMP 
riboswitches encoded in their 5’ UTR. For five of the riboswitches, we were unable to detect a 
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coding sequence downstream of the riboswitch, either based on the genome annotation or 
analysis of the reads in the regions (Table 3.2, Figures A1.1 to A1.16). For the remaining 11 
riboswitches, the transcription abundance of genes downstream of the riboswitch were 
significantly altered in the pDccA strain (Table 3.2). Transcript abundance was significantly 
reduced in the high c-di-GMP condition in the RNA-seq dataset for all but one of the genes (Cdi-
1-1) downstream of GEMM riboswitches. The expression of CD630_19900, the gene 
downstream of Cdi-1-1, was increased more than 30-fold. Of the genes downstream of putative 
class II riboswitches, all five showed increased expression in the high c-di-GMP condition. For 
many of these riboswitches (11 out of 16), the number of reads mapped to the riboswitches 
themselves was also significantly affected by increasing c-di-GMP levels (Table 3.2). For 
example, there were approximately 13-fold more normalized reads mapped to the riboswitch 
Cdi-1-1 in the high c-di-GMP condition. This observation suggests that c-di-GMP levels alters 
the activity of the promoters controlling transcription initiation for these genes, in addition to 
regulating via the riboswitches.  
 To validate the RNA-seq results and to confirm that regulation of transcription was due to 
increased c-di-GMP and not due to other potential functions of the DccA protein, we performed 
qRT-PCR for a subset of genes, focusing on those predicted to be regulated by riboswitches. 
This was done using C. difficile strains bearing vector, pDccA or pDccAmut, which encodes a 
catalytically inactive form of DccA (28), grown in the presence of nisin to induce dccA and 
dccAmut expression. Expression of all four of the genes 3’ of the class II c-di-GMP riboswitches 
was significantly increased in C. difficile with pDccA compared to the vector and pDccAmut 
controls (Table 3.3). Four out of the seven genes adjacent to GEMM riboswitches showed 
increased transcript levels in C. difficile pDccA (Table 3.4). The average transcript levels for the 
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other three genes was decreased in agreement with the RNA-seq data, but the differences did not 
meet statistical significance. For one of these genes, CD630_19900, the pDccA samples without 
inducer had 3.25 times as many normalized reads as the vector control even though the 
differences in intracellular c-di-GMP in the pDccA samples without inducer was only ~40% 
higher (680 nM vs 380 nM).  
 
 The observation that small increases in c-di-GMP might promote expression of some 
genes, but not others led us to hypothesize that these might differ in their responsiveness to c-di-
GMP. Differences between riboswitches of the same type can have large effects on the binding 
affinity of the riboswitches for their ligands and thus respond at differing thresholds of c-di-GMP 
(19, 34). In order to determine how responsive the transcription of these riboswitch-regulated 
genes were to c-di-GMP levels and whether there were different thresholds for expression of the 
different riboswitch-adjacent genes, we analyzed the abundance of transcripts of interest and 
related those results to the c-di-GMP concentration. To achieve a range of intracellular c-di-GMP 
concentrations, C. difficile with pDccA was grown with a range of concentrations of nisin (0 to 2 
μg/ml). C. difficile with vector and pDccAmut grown with 0 or 1 µg/mL nisin were included as 
controls (28). RNA was collected for qRT-PCR analysis and nucleotides were extracted for 
quantification by LC-MS/MS from the same samples. Intracellular concentrations of c-di-GMP 
were determined by determining the CFU/ml in each sample, and normalizing the determined c-
di-GMP concentration to the total cell volume extracted, as described previously (28). The 
control strains contained low intracellular c-di-GMP concentrations (between 40 and 380 nM) 
consistent with previously reported data for C. difficile (28). Induction of dccA with increasing 
levels of nisin led to a dose-dependent increase in c-di-GMP, ranging from 630 nM with no nisin 
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to 145 μM at the highest nisin concentration (Figure 3.3 and 3.4). In agreement with the RNA-
seq data, the transcript levels were reduced for 6 out of 7 genes predicted to be regulated by 
GEMM riboswitches, with the exception of the gene encoded downstream of Cdi-1-2, 
CD630_19900 (Fig 3.3). For the class II c-di-GMP riboswitch-regulated genes, increasing nisin 
concentrations resulted in a dose-dependent increase in transcript levels (Figure 3.4). In contrast, 
the transcript levels of the genes downstream of GEMM and class II riboswitches did not change 
in the presence of nisin in the vector and pDccAmut control strains (Tables 3.3 and 3.4), 
indicating that regulation occurs in response to increased c-di-GMP. For most of these genes, the 
differences in transcript levels are significant at a nisin concentration of 0.1, which corresponds 
to a 19-fold increase in the intracellular c-di-GMP concentration. Increasing nisin concentrations 
above 0.1 had only a modest additional effect on the expression of these genes. The trends for 
the genes downstream of the GEMM riboswitches are fairly consistent with the exception of Cdi-
1-1. The transcript levels of these genes decreased in a dose-dependent manner up to nisin 0.5 
µg/ml with decreases of between 3 and 10-fold. The class II riboswitches all show increased 
transcript levels as intracellular c-di-GMP increases. There is some variation in the magnitude of 
the response with CD630_32460 only showing a 5-fold increase over vector control at the 
highest intracellular c-di-GMP levels vs a 25-fold increase in CD630_28310 transcripts. This 
suggests similar regulation of these genes by c-di-GMP and is consistent with riboswitch 
regulation through the riboswitches. 
 
DISCUSSION 
 In this work, we set out to better define the transcriptional regulon of c-di-GMP in the 
human pathogen C. difficile. We found that c-di-GMP positively regulates 124 genes and 
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negatively regulates 42 others under the growth conditions tested (Figure 3.1B). These genes 
consist not only of genes previously demonstrated to be c-di-GMP regulated (e.g. flagellar and 
TFP genes), but also many others encoding proteins known or predicted to be involved in a wide 
array of cellular processes (Figure 3.1A).  
 Several of the proteins identified are predicted to localize to the cell envelope and the 
expression of a subset of these proteins in C. difficile enhanced biofilm formation, a process that 
is promoted by c-di-GMP in this bacterium (Figure 3.2) (32, 33). Two of the c-di-GMP regulated 
cell envelope proteins we identified (CD630_28310 and CD630_32460) were recently shown to 
be regulated by c-di-GMP (41). The cleavage of CD630_28310 (and possibly CD630_3246) 
from the surface of the cell is cleaved by another protein, ZmpI, which is itself negatively 
regulated by c-di-GMP (Table 3.2, Figure 3.3) (41). This presents an interesting scenario where 
increased intracellular c-di-GMP could promote attachment to a surface via these putative 
adhesins, and decreasing c-di-GMP levels could promote transcription of zmpI followed by ZmpI 
cleavage of the adhesins and dispersal of the bacteria. This model has yet to be tested, however.  
 For many of the remaining genes, the mechanism of regulation by c-di-GMP is unclear. 
The only predicted transcriptional regulators that we identified in our RNA-seq datasets were 
sigD and two response regulators (CD630_32670 and CD630_32660). Most of the genes we 
identified are not in the sigD regulon as reported by El Meouche et al (42), so we think sigD is 
unlikely to regulate many of these genes. The targets of the two response regulators have not 
been identified, so it is possible that they regulate the expression of a subset of the genes we 
identified. Interestingly, the response regulators are encoded in a potential operon downstream of 
the Cdi-2-2 riboswitch, so their expression is likely regulated by c-di-GMP directly. It is possible 
that binding of c-di-GMP to as yet undiscovered transcriptional regulators in C. difficile could be 
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responsible for regulation of some genes on our list. This is a common mechanism of regulation 
by c-di-GMP (17, 18, 43).  
 Of the 16 predicted c-di-GMP riboswitches in C. difficile, 11 of them are encoded near 
genes on the same coding strand, positioning them to regulate the expression of these 
downstream genes (Table 3.2) (32). We demonstrated that expression of all 11 of these genes 
was altered by increasing c-di-GMP concentration in vivo (Figure 3.3, 3.4). The magnitude of the 
response correlated with increasing c-di-GMP levels, and most of the genes responded to 
induction with 1ug/ml nisin, which corresponded to an increase in c-di-GMP of ~19-fold. The 
dynamic range of c-di-GMP in C. difficile is unknown, and whether a 19-fold increase in c-di-
GMP is commonly attained under physiological conditions is unclear. For one of the riboswitch-
adjacent genes (CD630_19990), the uninduced pDccA strain showed a statistically significant 
increase in transcript levels (3.4 fold) even though this strain only had 40% higher intracellular c-
di-GMP (630 nM vs 380 nM) than the uninduced vector control strain. This indicates that even 
small changes in c-di-GMP can affect the expression of some of these genes. 
 It can be tempting to assume that regulation by c-di-GMP occurs via the riboswitch for 
genes that are putatively riboswitch-controlled. However, there are multiple examples of ligands 
affecting promoter activity of genes downstream of their cognate riboswitch independent of 
riboswitch binding (34-36, 44). Thus, it is important to consider other possible mechanisms of 
regulation when determining the effects of riboswitches on transcription. To determine whether 
promoter regulation by c-di-GMP played a role in altered transcription of the putative 
riboswitch-controlled genes, we examined the response of the promoters alone to c-di-GMP. We 
demonstrated via reporter fusions that c-di-GMP levels regulate the expression of CD630_19900 
via the promoter. The riboswitch may still contribute to regulation of this gene’s transcription 
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because the fold change in alkaline phosphatase activity (~20) is much lower than the fold 
change in transcript levels measured by qRT-PCR (~100 fold). Constructing a fusion of this 
promoter and the WT riboswitch could answer this question. We also observed that for three 
genes adjacent to riboswitches in C. difficile (pilA1, CD630_33682, and zmpI), the promoter 
activity was not affected by increased c-di-GMP indicating that the regulation of these genes by 
c-di-GMP is likely due to the riboswitch.  
 One limitation of our approach to measure intracellular c-di-GMP is that we can only 
estimate c-di-GMP levels across the population, so the data may not accurately represent the c-
di-GMP concentration in individual cells due to population heterogeneity. However, this 
population heterogeneity is likely present in many contexts that are commonly regarded as high 
or low c-di-GMP conditions and may be more representative of responses than single cells or in 
vitro experiments (45-47). We have observed heterogeneity in the expression of flagellar genes 
using an mCherry reporter, which may also involve cell-to-cell variation in c-di-GMP levels 
(48). 
 The characterization of riboswitches in vivo allows us to better contextualize the function 
of these regulatory RNA structures in the larger c-di-GMP signaling networks of bacteria. This 
work expands the known c-di-GMP signaling network in C. difficile and demonstrates that the 
riboswitch-regulated genes in C. difficile are truly part of the c-di-GMP network. Given the 
importance of other c-di-GMP regulated genes for virulence (tcdA, tcdR) and persistence of this 
pathogen (pilA1), understanding the c-di-GMP network may lead to a better understanding of C. 




MATERIALS AND METHODS 
Bacterial growth conditions 
 C. difficile cultures were grown at 37 °C in an atmosphere of 5% CO2, 5% H2 and 90% 
N2 inside an anaerobic chamber (Coy). Overnight cultures of C. difficile were grown in 2-5 mL 
of TY medium (30 g/liter Bacto tryptone, 20 g/liter yeast extract, 1 g/liter thioglycolate) with 
antibiotics as necessary for plasmid maintenance. Except for overnights, C. difficile growth was 
in BHIS medium (37 g/ liter brain heart infusion, 5 g/liter yeast extract). Unless otherwise 
specified antibiotics were used at the following concentrations: thiamphenicol (Tm), 10 μg/ml; 
chloramphenicol (Cm), 10 μg/ml; ampicillin (Amp), 100 μg/ml; and kanamycin (Kn), 100 μg/ml. 
Nisin was added at 0.01-2.0 µg/ml as indicated to induce expression from the cpr promoter. 
 
RNA sequencing  
 Single colonies of 630Δerm bearing vector or pDccA were inoculated in TY medium and 
grown for ~16 hours, with 4 independent replicates per strain. Cultures were diluted 1:100 in 5 
mL of BHIS with thiamphenicol and grown to OD600 of 0.2. Nisin was then added to each 
culture for a final concentration of 1 μg/ml. Cultures were then grown to OD600 of 1.0 and then 
centrifuged for 10 minutes at 3,000 rcf. Supernatants were removed and pellets were suspended 
in 1 mL of TriSure (Bioline). Cells were added to ~250 L of 0.1 mm diameter zirconia beads 
(Biospec), lysed using a bead beater as described previously (28) and 200 L of chloroform was 
added. Cells were vortexed for 20 sec, incubated at room temperature for 10 minutes, and then 
centrifuged for 10 min at 13,000 rpm. The aqueous phase was transferred to a microcentrifuge 
tube and an equal volume of 100% isopropanol was added to precipitate the RNA. Samples were 
centrifuged at 13,000 x g for 10 minutes at 4 °C. Supernatants were removed, pellets were 
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washed with 1 ml of cold 70% ethanol and centrifuged again 13,000 x g for 10 minutes at 4 °C. 
Supernatants were removed and pellets were washed with 1 ml cold 70% ethanol and centrifuged 
again. Supernatants were removed, pellets were allowed to air dry, and pellets were suspended in 
50 μl of nuclease free water. RNA was treated with Turbo DNA-free (Ambion) to remove DNA 
and ribosomal RNA was depleted using a Ribozero (bacteria) rRNA removal kit (Illumina). 
Libraries were prepped, pooled and sequenced on a Hi-Seq 2500 sequencer (Illumina).  
 RNA sequencing analysis was performed using CLC Genomic Workbench (Qiagen). 
Transcripts were mapped to the CD630 genome (AM180355) and riboswitches were manually 
added based on the predictions by Lee et al. (20). Transcript reads for each gene were normalized 
to the total number of reads (transcripts per million reads or TPM) before calculating the fold 
change. Fold changes were calculating by dividing the TPM in the pDccA bearing strain by the 
TPM in vector control strain. Fold decreases are expressed as negative numbers instead of ratios. 
For example, if a transcript had 40 TPM in the pDccA bearing strain, and 20 TPM in the vector 
control strain, the fold change would be -2, not 0.5. Genes were considered regulated if the fold 
change between the means of the pDccA and vector bearing strains was greater than 2 and the p 
value was less than 0.05 following Bonferroni correction for multiple comparisons. 
 
Quantitative reverse transcription PCR (qRT-PCR) 
 Single colonies of C. difficile 630Δerm bearing vector, pDccA, or pDccAmut were 
inoculated in TY medium and grown for ~16 hours. Cultures were diluted 1:100 into 25 ml of 
BHIS with 10 µg/ml thiamphenicol and varying concentrations of nisin. For the vector and 
pDccAmut strains, two nisin concentrations, 0 µg/ml and 1 µg/ml, were used. For the pDccA 
strain, 7 concentrations were used: 0, 0.01, 0.1, 0.25, 0.5, 1.0 and 2.0 µg/ml. The cultures were 
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grown to exponential phase (OD600 of 1.0), and 3 ml samples were collected. The remaining 22 
ml was saved for quantification of c-di-GMP. Bacteria were centrifuged for 10 min at 2,000 x g, 
supernatants were removed, and bacteria were suspended in 1 ml TriSure. RNA isolation was 
carried out as described above for RNA-seq. Following RNA isolation, cDNA was synthesized 
using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). A total of 10 ng 
of cDNA template was used per qRT-PCR reaction. SensiMix SYBR Green (Bioline) was used 
for qRT-PCR. The data were analyzed using the 2−ΔΔCT method, with rpoC as a reference gene 
normalized to the stated reference condition or strain.  
 
Quantification of intracellular c-di-GMP 
 Serial dilutions were made of each culture grown for RNA isolation, CFU were 
enumerated. The remaining 22 ml of culture was centrifuged at 2500 x g for 10 minutes. 
Supernatants were removed, pellets were suspended in 1 ml PBS and transferred to 1.5 ml 
microcentrifuge tube. Samples were centrifuged at 10,000 x g and supernatants were removed. 
Pellets were suspended in 200 μl of extraction buffer (40% acetonitrile, 40% methanol, 0.1 N 
formic acid) and placed at -20 °C for 30 minutes. Samples were centrifuged at 12,000 × g for 5 
min at 4°C, and 200-μl aliquots of the supernatant were transferred to clean tubes and 
immediately neutralized by adding 8 μl of 15% (wt/vol) NH4HCO3. The c-di-GMP concentration 
in these samples was determined by UPLC/MS as described previously (49). Intracellular c-di-
GMP was calculated using estimates of C. difficile cell volume from electron micrographs and 




Construction of plasmids for expression of genes encoding cell wall proteins 
 The tet promoter from pRPF185 (50) was amplified by PCR using primers ATc_F + 
ATc_R. This PCR product was digested with the restriction enzymes EcoRI and SacI, ligated 
into similar digested pMC123 and transformed into E. coli DH5α. This plasmid (pRT1648) 
served as the vector control. The CD630_19870 gene was amplified from 630Δerm genomic 
DNA using primers CD630_19870_F and CD630_19870_R, digested with SacI and BamHI and 
ligated into similarly digested pRT1648. The resultant plasmid is p1987. The rest of the plasmids 
were constructed similarly to p1987 using primers LOCUS_TAG_F and LOCUS_TAG_R for 
the given locus tags. These plasmids were conjugated into C. difficile 630Δerm as described 
previously (28). 
 
Biofilm assays of putative cell envelope proteins 
 Overnight cultures of C. difficile grown in 2 ml of TY were diluted 1:100 in 1 mL 
modified BHIS (BHIS + 1% glucose + 50 mM sodium phosphate pH 7.5) containing 10 µg/ml 
thiamphenicol and 20 ng/ml ATc in 24 well plates. Bacteria were grown statically for 24 hours at 
37 °C anaerobically. After 24 hours, supernatants were removed, wells were gently washed once 
with PBS and stained with 1 ml of 0.1% crystal violet for 30 min. Crystal violet was removed 
and wells were washed twice with PBS. One ml of 95% ethanol was added to solubilize the stain 
and the absorbance at 570 nm was taken. A total of six independent overnight cultures were used 






Construction of reporter fusions  
 Promoter regions upstream of each riboswitch were amplified from 630Δerm genomic 
DNA using primers named cdiXXpromF and cdiXXpromR. For example, for Cdi-1-1, the 
promoter was amplified using Cdi1-1promF and Cdi1-1promR. Plasmid pRT1346 
(pSMB47::phoZ) (48) was digested with SalI and SphI. Amplified promoter regions and digested 
pRT1346 were added to Gibson assembly reactions. DH5α cells were transformed using 2 µl of 
the Gibson reactions. Plasmids were isolated from each confirmed strain. Plasmids were used to 
transform Bacillus subtilis BS49 as described previously (10). 
 Single colonies of the BS49 strains containing the reporter fusions were grown for ~5 
hours in BHIS supplemented with 2.5 µg/ml erythromycin and 10 ng/ml tetracycline. Bacillus 
cultures were then transferred into an anaerobic chamber and 100 μl of culture was spread evenly 
on the surface of a BHIS agar plate containing 2 mM KNO3 and allowed to dry for 5 min. After 
the B. subtilis had dried, 100 µl of an early stationary phase culture of C. difficile was spread 
evenly over the same BHIS plate. These conjugations were incubated for 24 hours then the 
bacterial growth was scraped from the plate and suspended in 300 μl of BHIS. After 
resuspension, 100 μl was spread evenly on BHIS plates supplemented with 2.5 µg/ml 
erythromycin. Plasmids pMC-Pcpr (vector) and pDccA were conjugated into these C. difficile 
strains as previously described (28). 
 
Alkaline phosphatase assay 
 Single colonies of reporter fusion strains bearing vector and pDccA were inoculated into 
2 ml TY medium containing 10 μg/ml thiamphenicol and grown for ~16 hrs. Cultures were then 
diluted 1:100 into 3 ml of BHIS containing 10 μg/ml thiamphenicol and various concentrations 
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of nisin (0, 0.01, 0.1, 0.25, 0.5, 1.0 and 2.0 μg/ml) as indicated. At mid-exponential phase (OD600 
of ~1.0), 1ml of each culture was collected and the bacteria were centrifuged for 1 min at 12,000 
rcf to pellet the bacteria. Supernatants were discarded and bacteria were stored at -20 °C. 






Figure 3.1. C. difficile genes regulated by c-di-GMP grouped by Riley classification of 
predicted gene products.  (A) c-di-GMP regulated genes from RNA-seq data grouped by Riley 
classification. (B) c-di-GMP regulated genes grouped by Riley classification and whether 
expression was increased or decreased in the pDccA strain (high c-di-GMP). Genes were 
included if the fold change in expression (differences in RPKM) was greater than 2-fold and p < 








Figure 3.2. Biofilm formation is promoted by ectopic expression of genes encoding cell 
envelope proteins.  Genes encoding putative cell envelope proteins were placed under the 
control of an ATc-inducible promoter and expressed ectopically from a plasmid in C. difficile 
with 20 ng/ml ATc. Biofilm formation was determined after 24 hours of static growth in 24-well 
plates by crystal violet staining. Six biological replicates were evaluated for each strain. Values 
are normalized to induced vector control. Individual symbols indicate a value from a single 
replicate, bars indicate the means and standard deviations. Data were analyzed by 1-way 














Figure 3.3. Transcript levels of genes downstream of GEMM riboswitches in C. difficile 
with increasing c-di-GMP.  Fold change of transcripts normalized to vector control are shown 
in blue. Intracellular c-di-GMP levels are shown in red (The same c-di-GMP data is used on each 
graph. Bars represent the geometric mean and geometric standard deviation of three biologically 









Figure 3.4. Transcript regulation of genes downstream of class II c-di-GMP riboswitches in 
C. difficile with increasing c-di-GMP.  Fold change of transcripts normalized to vector control 
are shown in blue. Intracellular c-di-GMP levels are shown in red. Each data point represents a 





Figure 3.5 Alkaline phosphatase reporter assays of riboswitch-adjacent gene promoters.  C. 
difficile 630erm bearing either vector or pDccA were grown to mid-exponential phase with the 
indicated concentration of nisin in g/ml. (A) Reporter activity of the pilA1 promoter alone 
(black), pilA1 promoter and native riboswitch (light gray), and pilA1 promoter and c-di-GMP 
unresponsive riboswitch (dark gray). (B) Reporter activity of the CD630_19900 promoter. (C) 
Reporter activity of the CD630_33682 promoter. (D) Reporter activity of the zmpI 
(CD630_28300) promoter. The means and standard deviations of 3 biological replicates are 
shown. Data were analyzed using one-way ANOVA with Dunnett’s post test to determine 





Table 3.1. Putative cell envelope proteins whose expression is regulated by c-di-GMP.  
Locus 
Fold Change 
(pDccA/vector) Predicted Function 
Riboswitch 
upstream? 
CD630_19870 4.32 cell wall protein 28 No 
CD630_27950 2.90 cell wall protein 11 No 
CD630_27960 -4.06 cell wall protein 10 No 
CD630_27970 -7.15 calcium-binding adhesion protein Yes 
CD630_28310 42.51 putative adhesin Yes 














Gene Chromosome region 
Fold Change 
(pDccA/vector)c 
Cdi-1-1 (-) 2296134 13.44 CD630_19900 (-) 2295867..2296352 31.90 
Cdi-1-2 (-) 3266578 -15.63 CD630_27970 (-) 3260792..3266755 -7.15 
Cdi-1-3 (+) 308778 -2.74 
CD630_02450 
(flgB) (+) 309272..309589 -15.06 
Cdi-1-4 (+) 3379981 1.02 ND     
Cdi-1-5 (-) 1142269 1.03 ND     
Cdi-1-6 (+) 2285923 -6.41 ND     
Cdi-1-7 (+) 2907226 1.19 ND    
Cdi-1-8 (+) 2297492 -9.25 CD630_19903 (+) 2297643..2297819 -7.78 
Cdi-1-9 (+) 2671809 -4.81 CD630_23090 (+) 2671951..2672127 -4.66 
Cdi-1-10 (-) 1653520 -2.07 ND     
Cdi-1-11 (+) 3936240 -8.49 CD630_33682 (+) 3936389..3936565 -8.90 
Cdi-1-12 (-) 3303074 -31.30 
CD630_28300 
(zmpI) (-) 3302613..3303275 -62.61 
Cdi-2-1 (-) 3801063 4.48 CD630_32460 (-) 3798299..3800482 4.29 
Cdi-2-2 (-) 3826609 2.34 CD630_32670 (-) 3825352..3826029 18.78 
Cdi-2-3 (-) 3306681 1.10 CD630_28310 (-) 3303646..3306564 42.51 
Cdi-2-4 (-) 4105796 4.10 
CD630_35130 
(pilA1) (-) 4105120..4105635 11.74 
a Riboswitch naming and start sites based on predictions by Sudarsan, et al. (2008), and Lee, et 
al. (2010). (+/-) indicate sense versus antisense strand 
b Fold change for the riboswitch region only 














Vector - 1.00 1.00 1.00 1.00 
Vector + 0.87 0.75 0.99 0.82 
pDccAmut - 1.14 1.07 1.27 1.12 
pDccAmut + 1.16 0.76 0.88 0.60 
pDccA - 1.25 1.88 2.43 2.22 
pDccA + 4.76* 17.35* 40.86* 18.44* 
+/- indicate cultures grown with 1 ug/ml nisin or without nisin, respectively. 























Vector - 1 1 1 1 1 1 1 
Vector + 1.09 1.46 1.21 0.81 0.85 0.61 0.85 
pDccAmut - 1.28 2.02 1.50 1.61 1.48 1.27 1.44 
pDccAmut + 1.27 1.82 1.57 2.04 2.12 1.25 0.90 
pDccA - 3.25* 0.70 1.12 1.75 1.58 1.18 1.72 
pDccA + 149.50* 0.24* 0.18* 0.59 0.31 0.34 0.15* 
+/- indicate cultures grown with 1 ug/ml nisin or without nisin, respectively. 
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CHAPTER 4: DISCUSSION 
SUMMARY OF RESULTS AND SIGNFICANCE 
 Over the past few decades, C. difficile has become an increasingly prevalent pathogen in 
the developed world causing approximately half a million infections each year in the United 
States alone (1-3). Despite the importance of this pathogen, we know very little about the factors 
that C. difficile uses to colonize and persist within the mammalian intestine following spore 
germination. Previous research in our lab and others has shown that high intracellular c-di-GMP 
concentrations in C. difficile lead to a variety of phenotypic changes, including decreased 
swimming motility, decreased toxin production, enhanced biofilm formation, autoaggregation of 
the bacteria in broth culture, and increased surface motility on hard agar surfaces (4-8). The 
transcription of type IV pilus (TFP) genes and the production of TFP are positively regulated by 
c-di-GMP (7, 8). The increased autoaggregation, biofilm formation and surface motility observed 
in bacteria with high intracellular c-di-GMP were shown to be at least partially dependent on 
type IV pili (7, 8).  
 The goal of my project in Chapter 2 was to determine the relevance of type IV pili and 
their regulation by c-di-GMP to the colonization of the intestine by C. difficile. We initially 
hypothesized that TFP were colonization factors of C. difficile based on our in vitro data and on 
evidence that TFP are used as colonization factors in other bacteria, including some intestinal 
pathogens (9-14). In the current study, we demonstrated that c-di-GMP promotes attachment of 
C. difficile to a variety of epithelial cells in vitro. Through the use of bacterial mutants lacking 
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TFP, we showed that TFP are dispensable for initial attachment to epithelial cells, but TFP 
contribute to prolonged adherence to epithelial cell monolayers. Additionally, we showed that 
the TFP-dependent adherence to epithelial cells requires c-di-GMP signaling through the 
riboswitch upstream of pilA1. To test our hypothesis that TFP are involved in colonization of the 
intestine, we infected antibiotic-treated mice with C. difficile spores from the parental strain 
(630Δerm) and two TFP-null strains with insertional mutations in the genes encoding the major 
pilin (pilA1) and the pilus assembly ATPase (pilB1). Contrary to our hypothesis, we found that 
the burden of C. difficile in the feces was similar for all infection for the first few days of 
infection. These results indicate that TFP are dispensable for establishing C. difficile colonization 
of the mammalian intestine. However, the pilus mutants were cleared more quickly from mice, 
and the TFP-null bacteria were recovered in fewer numbers in co-infection experiments after 3 
days, suggesting that TFP play a role in persistence of C. difficile in the host.  
How TFP promote maintenance of C. difficile host colonization is still undetermined, but 
there are a couple mechanisms that could explain the persistence defect in the pilA1 and pilB 
mutants. Perhaps the most straightforward mechanism for TFP to promote persistence would be 
to increase the strength of the interactions with the mucosal layer and prevent shedding. The 
observations that TFP promote prolonged adherence to host cells and that pilB mutant bacteria 
were more likely to be found loosely attached to the cecum than the parental strain are consistent 
with this mechanism. Interactions with the mucosa are known to be important for the persistence 
of Lactobacillus spp. in the gut (15-18). Interestingly, one of the mucin-binding proteins in L. 
johnsonnii and L. rhamnosus is the sortase-dependent pilin, SpaC (16, 19). Mutants lacking spaC 
were defective for mucin binding and persisted for about one week less than the parental strain 
(19). In Bifidobacterium breve, a mutant strain lacking the TadA pilus assembly ATPase was 
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defective for persistence in mice pre-colonized with other bacteria (20). Expression of the Tad 
locus of a different Bifidobacterium species in Lactobacilli promoted attachment of these 
bacteria to Caco-2 cells and fibrinogen (21). While the Tad and SpaBCA pili are not closely 
related to the pili produced by C. difficile, these data show that promotion of adherence to mucin 
as a mechanism for prolonged adherence is not without precedent. It is tempting to speculate that 
these three evolutionarily distinct pili converged on a similar mechanism to promote persistence 
of the bacteria within the intestine. It is also important to note that we have not directly 
determined whether type IV pili promote C. difficile adherence to mucus or to cells that produce 
mucus. Co-culture of C. difficile with mucus producing cells would provide an ideal environment 
to test the contributions of TFP to the mucous layer directly, but the lifespan of Caco-2 and HT-
29 intestinal epithelial cells in an anaerobic environment is on the order of a few hours. Several 
labs are developing improved models that would allow us to examine long-term interactions 
between C. difficile and the intestinal mucosa in vitro. A recent study developed a system using 
porous silk scaffolds seeded with primary myofibroblasts and a mix of Caco-2 and HT29 
intestinal epithelial cells to construct a 3D architecture and an artificial lumen (22). When grown 
submerged vertically in media to maintain anaerobiosis, these 3D systems supported growth and 
toxin production of C. difficile over 48 hours. C. difficile grown in these systems formed mat-like 
structures on the surface of the epithelial cell layers on the scaffold, supporting the hypothesis 
that C. difficile can grow in communities on the surface of epithelial cells. Similarly, a recent 
article on biorxiv reported a system for growing C. difficile anaerobically on the apical side of 
mucus-producing HT-29MTX cells while providing oxygen to the basolateral side. In 
collaboration with Dr. Nancy Allbritton (UNC-CH), we are developing an improved model using 
a stem-cell derived epithelium that tolerates anaerobiosis and includes mucus-producing goblet 
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cells. These systems would allow us to test the contributions of TFP to interactions with the 
mucus, but also the contributions of other c-di-GMP regulated factors that may play a role in 
adherence.  
 In Chapter 2, we demonstrated that a c-di-GMP regulated surface structure, the type IV 
pilus, is a C. difficile persistence factor. We previously demonstrated that c-di-GMP also 
negatively regulates production of flagella and toxins in C. difficile (5, 23). Because c-di-GMP 
signaling regulates these C. difficile virulence factors, characterizing the broader c-di-GMP 
network in C. difficile could lead to a better understanding of C. difficile pathogenesis. In 
Chapter 3, we determined the transcriptional regulon of c-di-GMP in C. difficile using RNA-seq 
analysis of C. difficile 630erm with basal levels of  c-di-GMP and with artificially increased c-
di-GMP levels. Among the most interesting classes of differentially expressed genes were those 
encoding proteins predicted to be localized to the cell envelope. We postulated that these 
proteins might be adhesins responsible for surface attachment in C. difficile, so we expressed 
them ectopically and found that expression of 4 of the 6 proteins enhanced C. difficile biofilm 
formation. These data point to a broader role for c-di-GMP in the rearrangement of the surface of 
C. difficile. One of the c-di-GMP regulated proteins that enhanced biofilm formation was 
CD630_32460. This protein is a putative adhesin and its expression was previously shown to be 
enhanced under high c-di-GMP conditions (24). This protein is also proteolytically cleaved by 
the ZmpI protease, which is negatively regulated by c-di-GMP (24). ZmpI also cleaves another 
c-di-GMP regulated protein, CD630_28310, which was previously shown to bind collagen (24-
26). The inverse regulation of these putative adhesin proteins and a protease that cleaves them 
leads to a model in which high levels of c-di-GMP promote adherence through production of the 
adhesins, and low levels of c-di-GMP promote detachment by inhibiting CD630_28310 and 
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CD630_32460 expression and increasing ZmpI production to cleave the existing adhesin 
proteins. Notably, reduced c-di-GMP also promotes flagellum biosynthesis and swimming 
motility, which would further facilitate C. difficile dispersal (27, 28). I tested whether ectopic 
expression of the cell envelope proteins would enhance binding to HT29 intestinal epithelial 
cells in vitro and did not see an effect, but these short-term binding experiments to one cell type 
are not a good model for binding to the intestinal mucus or epithelium. A co-culture system of C. 
difficile with mucus-producing cells would enable a straightforward test of this model allowing 
the manipulation of c-di-GMP levels and appropriate mutants to test the adherence of mutants 
lacking the adhesins or protease under both high and low c-di-GMP.   
 In addition to CD630_32460, CD630_28310, and zmpI, which are all riboswitch-
adjacent, we also determined that the expression of genes 3’ of 8 of the remaining 13 
riboswitches of C. difficile are regulated by c-di-GMP. To determine what intracellular 
concentration thresholds of c-di-GMP were required for these changes in transcription, we 
evaluated transcript abundance in C. difficile with a broad range of intracellular c-di-GMP. We 
found that for most genes, a c-di-GMP concentration of between 2 and 50-fold greater than basal 
c-di-GMP levels was sufficient to observe significant differences in transcription by qRT-PCR. 
Above the 50-fold threshold over basal c-di-GMP levels there were only small additional 
increases in transcriptional regulation –such extreme increases in c-di-GMP are unlikely to be 
physiologically relevant. The observation that small changes in c-di-GMP levels lead to 
appreciable changes in gene expression indicates that c-di-GMP signaling could be used by C. 
difficile to quickly adapt to changing environmental conditions. Indeed, c-di-GMP signaling 
networks have been shown to respond rapidly to environmental stimuli (29-31). Work from our 
lab has demonstrated that growth on a surface results in increased intracellular c-di-GMP levels 
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through an as yet unknown signal (8). It would make evolutionary sense for C. difficile in the 
intestine to respond to a surface by expressing adhesins that promote the stability of the C. 
difficile population within the gut.  
 The last section of Chapter 3 was devoted to determining whether the transcriptional 
changes we observed in riboswitch-adjacent genes were due to riboswitch regulation of 
transcription or through regulation of promoter activity by c-di-GMP. For three of the promoters 
we tested, there was weak or no stimulation of promoter activity by increased c-di-GMP levels in 
the cell, suggesting that c-di-GMP regulation of these genes occurs via the riboswitch or some 
other mode of regulation. Promoter activity of the CD630_19900 promoter, however, was much 
higher (~20-fold) in the high c-di-GMP conditions, indicating that at least some of the c-di-
GMP-dependent regulation of this gene occurs at the level of the promoter. CD630_19900 is 
particularly interesting because it is positively regulated by c-di-GMP, while all the other genes 
controlled by GEMM riboswitches are negatively regulated. The average sequence identity 
between the Cdi-1-1 (upstream of CD630_19990) and the other GEMM riboswitches is 69% 
(Figure A1.17), and yet the effects of c-di-GMP on the expression of these genes are completely 
opposite. This opposite mode of regulation demonstrates the potential versatility of riboswitch 
regulation and also suggests caution going forward not to assume that similar riboswitches 
produce similar effects.  
  Another set of genes we identified consists of a putative operon encoding a predicted two 
component regulatory system (TCRS) consisting of a histidine kinase (CD630_32660) and two 
response regulators (CD630_32670 and CD630_32650). In the canonical model of TCRS 
signaling, a stimulus is sensed by the histidine kinase which undergoes autophosphorylation and 
transfers the phosphate group to a phosphoreceiver (REC) domain of the response regulator (32, 
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33). Phosphorylation of the response regulator typically activates the response regulator (16, 17). 
Because the two response regulators we identified have conserved OmpR-family transcriptional 
regulator domains (based on the RefSeq database), we hypothesize that expression of a subset of 
genes that are regulated by c-di-GMP are controlled by these two response regulators. Work 
underway in our lab is currently testing this hypothesis.  
The mechanism by which c-di-GMP regulates transcription of many of the genes we 
identified is still unclear. The flagellar sigma factor, SigD, is regulated by c-di-GMP and has 
pleiotropic effects on the expression of other genes unrelated to flagellar biosynthesis (34). 
Counterintuitively, despite c-di-GMP regulation of sigD expression, many of the genes identified 
in the SigD transcriptome are not statistically different in our RNA-seq data set (4, 5, 34). It is 
possible that slight differences in growth between the experiments explains this discrepancy, and 
SigD could affect the transcription of some non-flagellar genes in our dataset. In other bacteria, 
c-di-GMP has been shown to bind to certain transcriptional regulators and alter the transcription 
of genes they regulate (35-37). It is possible that c-di-GMP binds to a transcriptional regulator in 
C. difficile that is responsible for altering transcription of a subset of c-di-GMP regulated genes 
as well. Such a protein could be discovered by pull-down assays of C difficile proteins using c-
di-GMP as bait. This approach has proven successful in identifying a c-di-AMP receptor in 
Staphylococcus aureus (38) 
The functions of most of the riboswitch regulated genes is unknown. CD630_19900 
contains two SH3_3 domains, which bind to other proteins to control peptidoglycan remodeling 
in some bacteria (39-41). One of the effects that increased intracellular c-di-GMP has on C. 
difficile is the elongation of cells into chains (4, 7, 24). Perhaps the CD630_19900 interactions 
with proteins to cause this chaining effect in C. difficile under high c-di-GMP conditions. It 
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could also be contributing the autoaggregation phenotype seen when intracellular c-di-GMP 
concentrations are elevated. CD630_27970 is annotated as a calcium binding adhesin, but its 
most well conserved domain is a peptidase M60 domain that has been shown to bind and cleave 
mammalian mucin in other bacteria (42, 43). It is tempting to speculate that this protein plays a 
role in mucin binding or degradation to facilitate colonization by C. difficile. The remaining two 
riboswitch regulated genes (CD630_33682, and CD630_32490) encode small hypothetical 




 The binding of C. difficile to the mucous layers of the epithelium could also provide a 
more stable population in the gut, which would be advantageous for the bacterium. The work in 
Chapter 2 demonstrated the contribution of TFP to C. difficile persistence and also hints at the 
possibility that bacteria closely associated with the intestinal epithelium could serve as reservoirs 
C. difficile infections. The increased duration of C. difficile would allow for the production of 
additional spores and increase the likelihood of transmitting spores to a new susceptible host. If 
the bacteria are also forming biofilms on the surface of the epithelium as seen in some animal 
models of diseases (44), these could serve as reservoirs for the bacteria. For C. difficile this could 
be especially important due to the high recurrence rates (~20-30%) in patients treated for C. 
difficile infections (45-47). Persistence of spores within patients has been postulated as one cause 
of relapse following cessation of antibiotics, but there is debate over what percentage of 
infections are reinfections with the same strain versus new infections with new strains of C. 
difficile (48). Persistent infections not only cause problems of recurrence, but also of 
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transmission, particularly in hospital settings where there is an increased percentage of people at 
high risk for CDI (49).  
 Another potential role of TFP in mediating intestinal persistence of C. difficile could be 
through the stabilization of interactions with other bacterial species and the formation of 
multispecies biofilms. The formation of monospecies C. difficile biofilms and adherence to 
epithelial cells were both partially dependent on TFP in vitro (8, 23). In the oral cavity where 
biofilms are common, the pili of Actinomyces oris are required for its coaggregation with 
Streptococcus oralis, an interaction that makes up one of the initial steps in biofilm development 
(50). The mucosa of the intestinal tract is normally free of biofilms perhaps owing to the rapid 
turnover rate of the mucin layer (estimated at 240 µm/h) and the ability of certain mucins to 
disrupt bacterial biofilms (51-53). Alterations to the mucus layers may have implications for 
disease development (54, 55). For example, aberrant mucus layers in the lungs of cystic fibrosis 
patients allow for the formation of long-lasting pathogenic biofilms (56). The importance of 
microbial biofilms in patients with inflammatory bowel disease (IBD) and ulcerative colitis (UC) 
is also being increasingly recognized (54, 57). Bacterial mats have been observed in animal 
models of C. difficile disease that are reminiscent of biofilm, but the importance of these biofilms 
is still unclear.  
 In patients with CDI, the mucin composition of the intestinal mucosa is altered (58). The 
mucus layer in these patients is more acidic, and the mucin composition shifts from the normally 
protective mucin MUC2 to enhanced production of MUC1 (58, 59). C. difficile was found to be 
more adherent to MUC1-rich mucus than mucus from healthy patients, and injection of C. 
difficile into human intestinal organoids was sufficient to decrease expression of MUC2 (58). C. 
difficile is often found in close association with mucus in patients with CDI as well as in animal 
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models of the disease (60-62). It is still unclear what role this alteration of mucin plays in the 
progression of CDI, but it is tempting to speculate that adherence of C. difficile to the mucin 
layer promotes the persistence of the bacterium. If adherence to mucins is important for 
infection, the increased production of more easily bound mucins coupled with the promotion of 
adherence by c-di-GMP, TFP, and other c-di-GMP regulated adhesins could be key to 
maintenance of C. difficile in the lower GI tract.  
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 Overall, the work in this dissertation has expanded the known regulon of c-di-GMP in C. 
difficile. We also demonstrated that c-di-GMP regulates TFP promote adherence to host cells and 
promote persistence in animal models of these disease. The data from chapter 2 coupled with the 
RNA-seq data that showed regulation of several putative adhesins c-di-GMP leads to the 
hypothesis that c-di-GMP promotes colonization of the mucous layer through multiple, possibly 
redundant mechanisms. Increasing availability of fluorescent reporters that function 
anaerobically and in C. difficile, as well as improved techniques in anaerobic microscopy, could 
allow for real time monitoring of C. difficile responses to surfaces sensing to determine which 
genes are regulated in response to surface-associated increases in c-di-GMP.It could also allow 
us to better understand what processes regulate the formation of C. difficile surface communities. 
These results could then be applied to in vitro co-culture of C. difficile and epithelial cells along 
with animal models to give us a better understanding of how C. difficile colonizes the intestine. 
This knowledge could be potentially be used to prevent colonization of C. difficile in patients at 
risk for CDI and prevent these infections from occurring. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 Overall, the work in this dissertation has expanded the known regulon of c-di-GMP in C. 
difficile. We also demonstrated that c-di-GMP regulated TFP promote adherence to host cells 
and promote persistence in animal models of these disease. The data from chapter 2 coupled with 
the RNA-seq data that showed regulation of several putative adhesins c-di-GMP leads to the 
hypothesis that c-di-GMP promotes colonization of the mucous layer in multiple different ways. 
Fusion of the promoters of the c-di-GMP regulated genes to fluorescent reporters that are now 
available for C. difficile could allow for real time monitoring of c-di-GMP responses to surface 
sensing to determine which genes are regulated in response to surface-associated increases in c-
di-GMP. These results could then be applied to in vitro co-culture of C. difficile and epithelial 
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APPENDIX: SUPPLEMENTAL FIGURES FOR CHAPTER 3 










CD630_01300 metK S-adenosylmethionine synthetase -2.15 3.3.16 
CD630_01480   uncharacterised protein -4.40 7.0.0 
CD630_01740 cooS Carbon monoxide dehydrogenase -8.61 3.5.2 
CD630_01750   putative oxidoreductase, Fe-S subunit -5.15 3.5.3 
CD630_01910   putative DNA glycosylase -2.06 2.2.3 
CD630_02110 licC CTP:phosphocholine cytidylyltransferase -10.96 4.1.9 
CD630_02120   putative sulfatase -9.03 3.3.19 
CD630_02130   putative spore coat protein -4.79 1.8.1 
CD630_02140   uncharacterised protein -5.77 7.0.0 
CD630_02260   putative lytic transglycosylase -6.05 3.3.21 
CD630_02270   conserved hypothetical protein -5.77 0.0.2 
CD630_02290 flgM 
Negative regulator of flagellin synthesis 
(Anti-sigma-d factor) -5.49 6.2.2 
CD630_02300   putative flagellar biosynthesis protein -5.56 1.1.1 
CD630_02310 flgK 
Flagellar hook-associated protein FlgK (or 
HAP1) -5.53 1.1.1 
CD630_02320 flgL 
Flagellar hook-associated protein FlgL (or 
HAP3) -5.68 1.1.1 
CD630_02330 fliW Flagellar assembly factor FliW -5.93 1.1.1 
CD630_02340 csrA Carbon storage regulator homolog CsrA -5.99 6.5.0 
CD630_02350 fliS1 Flagellar protein FliS1 -6.01 1.1.1 
CD630_02360 fliS2 Flagellar protein FliS2 -6.03 1.1.1 
CD630_02370 fliD 
Flagellar hook-associated protein 2 FliD 
(or HAP2) -6.45 1.1.1 
CD630_02380   conserved hypothetical protein -6.76 0.0.2 
CD630_02390 fliC Flagellin C -7.85 1.1.1 
CD630_02400   Glycosyltransferase -5.71 2.2.4 
CD630_02410   
flagella glycosylation phosphoserine 
phosphatase -5.88 2.2.4 
CD630_02420   
putative nucleoside triphosphate 
transferase -5.92 2.2.4 
CD630_02430   
flagella glycosylation methyltransferase 
domain protein -5.96 2.2.4 
CD630_02440   
putative CDP-
glycerol:Poly(glycerophosphate) 
glycerophosphotransferase -5.89 2.2.4 
CD630_02450 flgB Flagellar basal-body rod protein FlgB -15.09 1.1.1 




Flagellar hook-basal body complex 
protein FliE -15.47 1.1.1 
CD630_02480 fliF Flagellar M-ring protein FliF -13.28 1.1.1 
CD630_02490 fliG Flagellar motor switch protein FliG -12.07 1.1.1 
CD630_02500 fliH Flagellar assembly protein FliH -11.00 1.1.1 
CD630_02510 fliI ATP synthase subunit beta FliI -11.23 1.1.1 
CD630_02520 fliJ Flagellar protein FliJ -11.73 1.1.1 
CD630_02530 fliK Flagellar hook-length control protein FliK -11.30 1.1.1 
CD630_02540 flgD Basal-body rod modification protein FlgD -11.76 1.1.1 
CD630_02550 flgE 
Flagellar hook protein FlgE (Distal rod 
protein) -11.68 1.1.1 
CD630_02551 FlbD Flagellar protein FlbD -12.10 1.1.1 
CD630_02560 motA Flagellar motor rotation protein MotA -11.53 1.1.1 
CD630_02570 motB 
Flagellar motor rotation protein MotB 
(Chemotaxis protein MotB) -11.45 1.1.1 
CD630_02580 fliL 
Flagellar basal body-associated protein 
FliL -11.51 1.1.1 
CD630_02590 fliZ Flagellar protein FliZ -11.37 1.1.1 
CD630_02600 fliP Flagellar biosynthesis protein FliP -10.76 1.1.1 
CD630_02610 fliQ Flagellar biosynthetic protein FliQ -11.10 1.1.1 
CD630_02620 flhB 
Bifunctional flagellar biosynthesis protein 
FliR/FlhB -10.25 1.1.1 
CD630_02630 flhA Flagellar biosynthesis protein FlhA -10.14 1.1.1 
CD630_02640 flhF 
Flagellar biosynthesis regulator FlhF 
(Flagella-associated GTP-binding protein) -9.89 1.1.1 
CD630_02650 flhG Flagellar number regulator FlhG -9.76 1.1.1 
CD630_02660 fliA 
RNA polymerase sigma-28factor for 
flagellar operon -9.94 6.2.1 
CD630_02670   putative flagellar protein -10.10 1.1.1 
CD630_02671   putative flagellar protein -11.82 1.1.1 
CD630_02680 flgG1 
Flagellar hook-basal body complex 
protein FlgG1 -9.59 1.1.1 
CD630_02690 flgG Flagellar basal body rod protein FlgG -10.09 1.1.1 
CD630_02700 fliM Flagellar motor switch protein FliM -9.66 1.1.1 
CD630_02710 fliN1 Flagellar motor switch phosphatase FliN1 -5.85 1.1.1 
CD630_02280 fliN Flagellar motor switch protein FliN -10.19 1.1.1 
CD630_02720   conserved hypothetical protein -9.93 0.0.2 
CD630_02730 htpG 
Heat shock protein 90 (Heat shock 
protein HtpG)(High temperature protein 
G) -4.17 1.3.1 
CD630_02731   conserved hypothetical protein -3.05 0.0.2 
CD630_02850   
PTS system, mannose/fructose/sorbose 
IIB component 2.75 1.5.3 
CD630_02860   
PTS system, mannose/fructose/sorbose 
IIA component 2.43 1.5.3 
 
123 
CD630_02880   
PTS system, mannose/fructose/sorbose 
IIC component 2.84 1.5.3 
CD630_05110 tndX 
Recombinase site-specific resolvase 
family Tn5397, CTn3-Orf3 -12.90 5.1.4 
CD630_05290   putative membrane protein -5.06 4.1.6 
CD630_05600 nfo Endonuclease IV -5.33 2.2.3 
CD630_05800 gapN 
Glyceraldehyde-3-phosphate 
dehydrogenase (NADP(+)) (GADPH) -11.79 3.5.5 
CD630_05870   uncharacterised protein 2.02 7.0.0 
CD630_05880   uncharacterised protein 2.06 7.0.0 
CD630_06180   Transcriptional regulator, LytR family -2.59 6.5.0 
CD630_06190   conserved hypothetical protein -7.92 0.0.2 
CD630_06200   conserved hypothetical protein -8.54 0.0.2 
CD630_06210   putative membrane protein -6.87 4.1.6 
CD630_06220   conserved hypothetical protein -7.09 0.0.2 
CD630_06720   conserved hypothetical protein -4.36 0.0.2 
CD630_07570   putative c-di-GMP phosphodiesterase -5.35 6.5.0 
CD630_10910 int1 Integrase Tn1549-like, CTn4-Orf34 2.68 5.1.4 
CD630_11030   
putative conjugative transposon protein 
Tn1549-like, CTn4-Orf21 4.91 5.1.4 
CD630_11031   
putative conjugative transposon protein 
Tn1549-like, CTn4-Orf20 3.90 5.1.4 
CD630_11040   
putative conjugative transposon protein 
Tn1549-like, CTn4-Orf19 3.03 5.1.4 
CD630_11250   Nitroreductase-family protein -6.05 7.0.0 
CD630_11260   Transcriptional regulator, AraC family -4.61 6.3.2 
CD630_12790 iscS2 Cysteine desulfurase -5.22 3.3.19 
CD630_12800   
fe-s iron-sulfur cluster assembly protein, 
nifu family -3.54 3.5.3 
CD630_14700   
putative rhodanese-like domain-
containing protein -19.49 1.4.2 
CD630_14740   putative rubrerythrin (Rr) -8.36 1.4.2 
CD630_14790 feoB1 Ferrous iron transport protein B 2.24 1.6.3 
CD630_15240   putative rubrerythrin -2.56 1.4.2 
CD630_15680   conserved hypothetical protein -7.98 0.0.2 
CD630_15800 hom2 Homoserine dehydrogenase 2.73 3.1.0 
CD630_16970 ribH 6,7-dimethyl-8-ribityllumazine synthase -3.74 3.2.13 
CD630_16980 ribBA 
Riboflavin biosynthesis protein ribBA 
[Includes: 3,4-dihydroxy-2-butanone 4-
phosphate synthase; GTP cyclohydrolase-
2] -2.74 3.2.13 
CD630_17290   putative sodium:phosphate symporter -9.01 1.5.2 
CD630_17770   putative arsenate reductase -5.61 1.4.2 
CD630_17940   conserved hypothetical protein 5.11 0.0.2 
CD630_17950   conserved hypothetical protein 5.76 0.0.2 
CD630_18220 bcp putative thiol peroxidase -13.15 1.4.2 
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CD630_18230   
conserved hypothetical protein, UPF0246 
family -10.41 0.0.2 
CD630_18240   P-type calcium transport ATPase -3.15 1.5.2 
CD630_18820   Site-specific recombinase -3.84 5.1.4 
CD630_18990   putative dCMP deaminase -13.88 7.0.0 
CD630_19870 cwp28 putative cell wall binding protein cwp28 4.31 4.1.8 
CD630_19900   putative protein with SH3 domain 35.08 0.0.2 
CD630_19903   conserved hypothetical protein -2.00 0.0.2 
CD630_20460   conserved hypothetical protein -9.50 0.0.2 
CD630_21151   uncharacterised protein -11.51 7.0.0 
CD630_21170 trxB2 Thioredoxin reductase -5.23 3.2.15 
CD630_21580 gabT 4-aminobutyrate aminotransferase 2.06 3.3.20 
CD630_22090   putative GTP-binding protein, HflX type -4.09 7.0.0 
CD630_23090   conserved hypothetical protein -2.64 0.0.2 
CD630_23270   
PTS system, fructose/mannitol family IIA 
component 5.32 1.5.3 
CD630_24760   gnat family acetyltransferase -3.38 7.0.0 
CD630_24770   uncharacterised protein -4.50 7.0.0 
CD630_24860   PTS system, fructose-like IIC component -2.44 1.5.3 
CD630_24870   PTS system, fructose-like IIB component -2.64 1.5.3 
CD630_24880   PTS system, fructose-like IIA component -3.23 1.5.3 
CD630_24890   
Transcription antiterminator, PTS operon 
regulator -3.91 6.5.0 
CD630_27950 selA 
L-seryl-tRNA(Sec) selenium transferase 
(Selenocysteine synthase) (Sec synthase) 
(Selenocysteinyl-tRNA(Sec) synthase ) 2.89 2.2.1 
CD630_27960 selD 
Selenide, water dikinase 
(Selenophosphate synthetase) (Selenium 
donor protein) -4.07 2.2.1 
CD630_27970 comE Competence protein ComEA -7.14 4.1.6 
CD630_28300   uncharacterised protein -65.96 7.0.0 
CD630_28310   putative adhesin 42.42 4.1.5 
CD630_28410   putative amidohydrolase -11.37 3.4.5 
CD630_28450 rbr1 Rubrerythrin 2.50 1.4.2 
CD630_28460   conserved hypothetical protein 2.42 0.0.2 
CD630_28470   conserved hypothetical protein 2.38 0.0.2 
CD630_28480   conserved hypothetical protein 2.37 0.0.2 
CD630_28750 fhuC 
ABC-type transport system, ferrichrome-
specific ATP-binding protein -3.78 1.6.3 
CD630_29950 nrdE 
Ribonucleoside-diphosphate reductase 
subunit alpha (Ribonucleotide reductase 
large subunit) -4.39 3.3.11 
CD630_30100   putative cytochrome C assembly protein -2.30 3.2.6 
CD630_30330 trxA1 Thioredoxin -3.78 3.2.15 
CD630_30390   putative ATPase -6.98 7.0.0 
CD630_30400   conserved hypothetical protein -10.44 0.0.2 
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CD630_30990   putative amidohydrolase, M20D family -2.08 2.1.4 
CD630_31000   
putative C4-dicarboxylate anaerobic 
carrier,DcuC family -2.09 1.5.3 
CD630_32110   conserved hypothetical protein 2.07 0.0.2 
CD630_32150   
ABC-type transport system, glycine 
betaine/carnitine/choline ATP-binding 
protein -5.74 1.6.2 
CD630_32160   
ABC-type transport system, glycine 
betaine/carnitine/choline permease -8.39 1.6.2 
CD630_32460   putative surface protein 4.28 4.1.8 
CD630_32640   
Fragment of conserved hypothetical 
protein (C-terminal region) 3.37 0.0.2 
CD630_32650   Two-component response regulator 17.57 6.1.2 
CD630_32660   Two-component sensor histidine kinase 18.37 6.1.1 
CD630_32670   Two-component response regulator 18.74 6.1.2 
CD630_33230   conserved hypothetical protein -2.25 0.0.2 
CD630_33250   conserved hypothetical protein 2.10 0.0.2 
CD630_33260   
Integrase, lambdoid phage family Tn916-
like,CTn6-Orf1 2.14 5.1.2 
CD630_33270   
putative conjugative transposon protein 
Tn916-like, CTn6-Orf2 2.12 5.1.4 
CD630_34770   putative dCMP deaminase -2.00 3.3.11 
CD630_35040   
putative type IV prepilin peptidase, A24A 
family 3.18 4.1.5 
CD630_35050   putative twitching motility protein PilT 3.49 4.1.5 
CD630_35060   conserved hypothetical protein 4.28 0.0.2 
CD630_35070   putative type IV pilin 4.40 4.1.5 
CD630_35080   putative type IV pilin 4.69 4.1.5 
CD630_35090   putative type IV pilus assembly protein 4.67 4.1.5 
CD630_35100   putative membrane protein 5.08 4.1.6 
CD630_35110   putative type IV pilus secretion protein 5.28 4.1.5 
CD630_35120   
putative type IV pilus transporter 
system,ATP-binding 4.89 4.1.5 
CD630_35130   putative pilin protein 11.72 4.1.5 
CD630_35250   
ABC-type transport system, iron-family 
extracellular solute-binding protein -9.35 1.5.5 
CD630_35260   
ABC-type transport system, iron-family 
permease -9.01 1.5.5 
CD630_35270   
ABC-type transport system, iron-family 
ATP-binding protein -9.81 1.5.5 
CD630_36100   putative glyoxalase -11.82 1.4.2 
CD630_36400   putative ribokinase family sugar kinase -2.01 3.4.3 
CD630_36410   conserved hypothetical protein -4.38 0.0.2 
CD630_36420   putative selenocysteine synthase -4.98 2.2.1 
CD630_36430   Dihydroorotase -5.02 3.7.2 
a Riley Class identification based on Pettit et al. BMC Genomics 2014.  
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Table A1.2 Plasmids and Strains used in this study 
Plasmids Description 
pMC123 E. coli – C. difficile shuttle vector; AmpR, CmR/TmR 
pMC-Pcpr pMC123 with cpr promoter in the multiple cloning site 
pDccA pMC-Pcpr ::dccA (CD630_14200) 
pDccAmut pMC-Pcpr ::dccAmut (AADEF) 










F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17(rκ -, mκ+) phoA supE44 thi-1 gyrA96 relA1 λ- tonA 
Bacillus subtilis BS49 CU2189::Tn916 
C. difficile 630dErm 
Ribotype 012, erythromycin-sensitive derivative of C. 
difficile 630 
630dErm pSMB47::PCD630_19900-phoZ 
CD630_19900 promoter fused to phoZ and integrated on 
the C. difficile chromosome  
630dErm pSMB47::PCD630_33682-phoZ 
CD630_33682 promoter fused to phoZ and integrated on 
the C. difficile chromosome  
630dErm pSMB47::PzmpI-phoZ 
zmpI promoter fused to phoZ and integrated on the C. 
difficile chromosome  
630dErm pSMB47::PpilA1-phoZ 
pilA1 promoter fused to phoZ and integrated on the C. 
difficile chromosome  
630dErm pSMB47::PpilA1-UTRWT-phoZ 
pilA1 promoter and native riboswitch fused to phoZ and 
integrated on the C. difficile chromosome  
630dErm pSMB47::PpilA1-UTRA70G-phoZ 
pilA1 promoter with A70G mutation in the riboswitch 





Table A1.3 Olignucleotides used in this study 





























Figure A1.1 RNA-sequencing reads for the region surrounding Cdi-1-1. Reads in red match 










Figure A1.2 RNA-sequencing reads for the region surrounding Cdi-1-2. Reads in red match 




Figure A1.3 RNA-sequencing reads for the region surrounding Cdi-1-3.  Reads in red match 
the sense strand of the genome and reads in green match the antisense strand. 




Figure A1.4 RNA-sequencing reads for the region surrounding Cdi-1-4.  Reads in red match 
the sense strand of the genome and reads in green match the antisense strand. Yellow reads 









Figure A1.5 RNA-sequencing reads for the region surrounding Cdi-1-5. Reads in red match 
the sense strand of the genome and reads in green match the antisense strand. Yellow reads 




Figure A1.6 RNA-sequencing reads for the region surrounding Cdi-1-6. Reads in red match 










Figure A1.7 RNA-sequencing reads for the region surrounding Cdi-1-7. Reads in red match 
the sense strand of the genome and reads in green match the antisense strand. Yellow reads 




Figure A1.8 RNA-sequencing reads for the region surrounding Cdi-1-8. Reads in red match 
the sense strand of the genome and reads in green match the antisense strand. Yellow reads 








Figure A1.9 RNA-sequencing reads for the region surrounding Cdi-1-9. Reads in red match 
the sense strand of the genome and reads in green match the antisense strand. Yellow reads 




Figure A1.10 RNA-sequencing reads for the region surrounding Cdi-1-10. Reads in red 
match the sense strand of the genome and reads in green match the antisense strand. Yellow 









Figure A1.11 RNA-sequencing reads for the region surrounding Cdi-1-11.  Reads in red 
match the sense strand of the genome and reads in green match the antisense strand. Yellow 




Figure A1.12 RNA-sequencing reads for the region surrounding Cdi-1-12. Reads in red 
match the sense strand of the genome and reads in green match the antisense strand. Yellow 









Figure A1.13 RNA-sequencing reads for the region surrounding Cdi-2-1.  Reads in red 




Figure A1.14 RNA-sequencing reads for the region surrounding Cdi-2-2.  Reads in red 









Figure A1.15 RNA-sequencing reads for the region surrounding Cdi-2-3.  Reads in red 




Figure A1.16 RNA-sequencing reads for the region surrounding Cdi-2-4.  Reads in red 




Figure A1.17. Sequence analysis of the GEMM riboswitches in C. difficile.  (A) Alignment of 
the sequences by Clustal Omega. Asterisks represent bases that are conserved for all four 
riboswitches. (B) Cladogram representing the relative sequence identity between the 




Figure A1.18. Sequence analysis of the class II c-di-GMP riboswitches in C. difficile.          
(A) Alignment of the sequences by Clustal Omega. Asterisks represent bases that are conserved 
for all four riboswitches. (B) Cladogram representing the relative sequence identity between the 
riboswitches. (C) Percent sequence identity for each pair of riboswitches. 
 
 
 
 
 
